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Prevalence of chronic diseases in the United States keeps increasing in recent years. There are 
approximately four in ten adults having chronic diseases in America. Chronic diseases include 
obesity, aging, heart diseases, cancer and many others. This thesis mainly focuses on obesity and 
aging. Skeletal muscle performance is impaired in obesity and aging conditions. One common 
reason causing this could be higher fat mass and lower muscle mass. However, there is no study 
showing what pathways are involved in the imbalance of body composition. Therefore, the first 
objective of the thesis is to determine gene expression of selected pathways in the skeletal 
muscle from young and old, lean and overweight/obese participants. Leucine has been shown to 
activate protein translation initiation pathway mTORC1 in skeletal muscle. Further, mTORC1 is 
also known for regulating a variety of cellular pathways. Thus, the second objective of the thesis 
is to determine the effect and mechanisms of leucine supplementation on preventing intracellular 
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 According to the report from Center for Disease and Control, there are six in ten adults in 
the US having one chronic disease and four in ten adults are having two or more chronic diseases 
(4). Chronic diseases such as obesity and aging are the leading cause for disability and death, and 
leading contributor for the annual health care cost of $3.5 trillion in the United States (4). Many 
factors contribute to the development of chronic diseases including smoking and exposure to 
second-handed smoke, poor nutrition including low vitamin, low protein, high sodium, and high 
saturated fats containing diets, sedentary life style, and excessive alcohol use (4). Prevalence of 
obesity and aging keeps rising in the United States. There are 15.2% of total population aged 65 
or over, and there are 42.4% of total population obese in the United States (1, 13). Skeletal 
muscle taken from obese or aged adults shared some commons such as reduced relative muscle 
mass, increased fat infiltration, and increased fat accumulation surrounding muscle (5, 12). 
Muscle protein kinetics balance is correlated muscle growth, as muscle atrophy happens when 
muscle protein breakdown (MPB) is higher than muscle protein synthesis (MPS). Reduced basal 
MPS was reported in skeletal muscle from older or obese adults, compared to skeletal muscle 
from young or lean adults (10, 11). With the aspect of MPS, blunted activation of protein 
synthesis-related molecular pathway, the mechanistic target of rapamycin complex 1 pathway 
(mTORC1), was reported from skeletal muscle from diet-induced obese mice or aged mice (9, 
18). With the aspect of MPB, there are three molecular pathways involved, autophagy, ubiquitin-
proteasome system (UPS), and Ca2+-calpain pathway. Autophagy and UPS are widely studied 
than Ca2+-calpain pathway. Especially in skeletal muscle, higher signal of autophagy and UPS 
are shown in the muscle from diet-induced mice or aged mice (6, 7). Fat accumulation could be 




production in cells, mitochondria has been shown reduced in total amount in skeletal muscle 
from obese or aging adults (5, 17). In addition, mitochondria is involved in fat oxidation as the 
rate-limiting enzyme, carnitine palmitoyltransferase 1 (Cpt1), localizes on the out membrane of 
mitochondria. Fat oxidation and Cpt1 enzymatic activity are shown reduced in muscle of obese 
adults (14). Further, increased gene expression related to fat synthesis is shown in muscle of 
aging adults (5). However, information on gene expression related to protein breakdown and 
energy metabolism are still lacking in skeletal muscle under obesity and aging conditions. 
Therefore, the first objective of this dissertation is to compare the gene expression of autophagy, 
UPS, mitochondria, and fat metabolism between young and old, or lean and obese, adults. It is 
hypothesized that muscle from older and obese adults had higher expression of autophagy, UPS, 
and fat synthesis-related genes; and lower expression of mitochondrial biogenesis and fat 
oxidation-related genes, compared to young and lean adults. 
 Nutrition such as leucine or branched-chain amino acids (BCAA)-enriched 
supplementation is a good option to improve skeletal muscle health in both obesity and aging 
conditions (16, 19). In addition, previous study from our lab showed BCAA-enriched high 
protein diet reduced adiposity in the skeletal muscle of obese Zucker rats (8). BCAA are 
different from other essential amino acids as the first step, conversion of BCAA to branched-
chain keto-acids (BCKA) of their catabolism undergoes in skeletal muscle or central nervous 
system (15). Furthermore, leucine is different from valine and isoleucine as it can activate 
mTORC1 to improve translational initiation in skeletal muscle (2, 3). However, the effect of 
leucine supplementation on skeletal muscle health in obesity is still unclear. Therefore, the 




obese skeletal muscle. It is hypothesized that leucine supplementation could reduce lipid 
deposition in obese skeletal muscle through mTORC1 pathway. 
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Skeletal muscle health has been shown to be damaged under obesogenic conditions in several 
aspects such as decreased muscle mass, poor physical performance, and increased fat deposition. 
Leucine is well-known as the activator of the mechanistic target of rapamycin complex 1 
(mTORC1) pathway, which plays a central role in mediating protein turnover. Protein turnover is 
suggested to be directly linked to muscle mass. Therefore, the objective of the present review is 
to discuss current available evidence about the effect of leucine on improving skeletal muscle 
health under obesogenic conditions and underlying mechanisms. We conclude that as a 
nutritional intervention for obesity, leucine is able to increase protein synthesis, decrease protein 
breakdown, and improve mitochondrial function, and fatty acid catabolism. Regarding to current 
theory of elevated plasma level of leucine as a biomarker for obesity, we speculate the possible 
alterations in enzymes such as muscle specific BCATm and BCKDH would be responsible for 
elevated circulating leucine concentration observed in obese patients. Overall, although more and 
more studies have revealed the positive effects of leucine on skeletal muscle under obesogenic 
conditions, the exact mechanisms underlying the action of leucine is still unclear, and 
understanding of adipose-muscle tissue crosstalk would benefit for explaining high circulating 
BCAAs level in obese patients. 
 
2.2 Introduction  
According to the Centers for Disease Control and Prevention (CDC), 42.4% of US adults are 




alcoholic fatty liver disease (NAFLD) and certain types of cancer are also associated with 
obesity (19). Physiologically, skeletal muscle from obese patients is impaired in many aspects 
such as structure (muscle fiber composition) and muscle strength (contractile force) (27, 78-80). 
Muscle impairment in obesity is also associated with poor quality of life, decreased motility, 
self-care, usual activities and pain/discomfort (15). The health complications associated with 
obesity place a heavy economic burden on governments around the world (29). It is estimated 
that $149.4 billion is invested annually for prevention and treatment of obesity in the United 
States (51). In most cases, obesity is caused by over-nutrition. Over-nutrition results in over-
accumulation of adipose tissue such as subcutaneous fat and visceral fat, which causes imbalance 
in body composition, in which higher fat mass and lower muscle mass found in obese patients 
(70). A better understanding of the molecular pathways dysregulated under obesity conditions 
will benefit for further designing of intervention to reduce weight. Currently, several treatments 
targeting weight loss such as exercise (2) and healthy diets (31) have been shown to improve 
muscle health. For example, leucine-enriched high protein diet increased muscle protein 
synthesis regulator activity, mechanistic target of rapamycin complex 1 (mTORC1), in obese 
Zucker rats (30). Leucine, one of branched-chain amino acids (BCAAs), bypasses portal venous 
system to undergo the first and reversible step of catabolism in before entering the circulating 
system. The enzyme catalyzes this step is mitochondrial form of branched-chain amino acid 
transaminase (BCATm),which highly expresses in skeletal muscle, and cytosolic form of BCAT 
(BCATc), which highly expresses in brain and peripheral nerves. This feature makes leucine 
metabolism unique among amino acids. Leucine functions not only as a building block for 
protein synthesis and a source for ATP production, but also as an activator of mTORC1, and 




adipogenesis, lipid metabolism and so on (69). Impairments in metabolic pathways such as 
mTORC1 (88), autophagy (28), mitochondrial function (50), and fatty acid metabolism (49) have 
been reported in the skeletal muscle of individuals with obesity and animal models of diet-
induced obesity. In recent years, research has focused on the effect of leucine supplementation 
on skeletal muscle under obesogenic conditions using animal models and identifying potential 
mechanisms of action for leucine’s role in obesity treatment and or prevention (6, 9, 32, 55, 59, 
65, 96). However, the detailed mechanisms involved in the effect of leucine on improving 
muscle functions in obesity conditions is less discussed. Thus, the present review is aimed to 
summarize and discuss current evidence regarding mechanisms involved in skeletal muscle 
impairment under obesogenic conditions and the role of leucine supplementation in improving 
muscle function. In addition, this review aims to provide possible new directions for future 
studies. 
 
2.3 Mechanisms underlying skeletal muscle impairments in obesity 
2.3.1 Imbalanced protein turnover in obese muscle 
Skeletal muscle is constantly synthesizing and degrading proteins. The difference between 
muscle protein synthesis (MPS) and muscle protein breakdown (MPB) is defined as net balance 
(NB). Deficits in MPS and/or increase in MPS, which results in a negative net balance, will 
cause loss of skeletal muscle protein. Conversely, accretion of skeletal muscle protein can be a 
result of rise in MPS and/or reduction in MPB. Muscle mass is shown to be correlated with 
muscle protein turnover. For example, it is shown that higher dietary protein intake is associated 
with higher skeletal muscle mass (77). In addition, a significant reduction in MPS in human 




days of bed rest (68). In contrast to MPS, measurement of MPB is still a technical challenge 
since the current available methods, endogenous labeling of 2H-alanine by 2H2O consumption 
(44) and L-ring-13C6-phenylalanine infusion (81), measuring MPB through indirectly calculating 
the disappearance rate of labeled alanine or phenylalanine. Recent study compares these two 
methods and reports failure in MPB measurements (43). In addition, these researchers consider 
labeling essential amino acids tracer is inappropriate as possible significant and prolonged 
labeled amino acid recycling (43). A novel method using labeled methyl-D3-
13C-methionine is 
shown to measure MPB in C2C12 myotubes, but this method still needs further verification in 
human muscle (87). Thus, measurement of MPB-related pathways such as autophagy is 
suggested to be an add-on to tracer methods. 
Increased MPB in the post-absorptive state has been reported in young healthy obese men, 
and MPS in obese muscle is increased to a lower level than lean muscle in post-absorptive state 
(38). A similar reduction in MPS response under fed conditions was reported in obese elderly 
(64). Rate of labeled phenylalanine appearance, an indicator for MPS, is reported to be lower in 
skeletal muscle from obese young adults compared with lean young adults (5). Increased MPB is 
shown to be correlated with moderate upper-body obesity (47). This has also confirmed in 
animal studies (73). For example, decreased 24h MPS was demonstrated in gastrocnemius 
muscle from obese Zucker rats (66). In addition, increased relative ratio of urinary muscle 
derived 3-methylated-histidine to creatine, which reflects degradation of myofibrillar proteins as 
described in previous paragraph, is shown in muscle of obese Zucker rats (73). These results 




2.3.2 Blunted mTORC1 response in obese muscle 
The mammalian Target of Rapamycin Complex 1 (mTORC1) is a well-established pathway 
for regulating protein translation initiation in skeletal muscle (37). The mTORC1 are shown 
simultaneously dysregulated in skeletal muscle under obesogenic conditions (8, 66, 89). There 
are two direct downstream proteins of mTORC1, S6 Kinase 1 (S6K1) and eukaryotic translation 
initiation factor 4E binding protein (4EBP1), known as indicators of mTORC1 activity (26, 90). 
Relative content of phosphorylated S6K1 and 4EBP1 are reduced in vastus lateralis muscle from 
obese patients (88). Blunted activation of mTORC1 to feeding and exercise in vastus lateralis 
muscle has also reported in obese patients (7). In addition, in genetic obese animal model, it has 
been demonstrated that decreased phosphorylation of S6K1 in the skeletal muscle (66). Mice fed 
a high-fat diet showed decreased phosphorylation level of S6, target of S6K1, in muscle, and this 
is exacerbated by addition of rapamycin (61). Collectively, these results suggest a blunted 
mTORC1 response to MPS-improving methods under obesogenic conditions (Figure 2.1A). 
2.3.3 Dysfunctional skeletal muscle mitochondria in obesity 
Mitochondria are responsible for intracellular energy metabolism in skeletal muscle as the 
center for ATP production. All energy sources including carbohydrates, fat, and proteins finally 
enter the tricarboxylic cycle (TCA) and electron transport chain (ETC) in mitochondria for 
energy production in the form of ATP in muscle. Mitochondria sense intramuscular energy status 
in the form of the ratio of ATP to AMP (86). Therefore, activity of enzymes in the ETC directly 
determines ATP production in skeletal muscle. In research comparing mitochondrial ETC in 
skeletal muscle taken from lean and obese individuals, complex I of ETC that initiates the 
electron transport, NADH: O2 oxidoreductase was showed less active in skeletal muscle from 




reactive oxygen species (ROS) from mitochondrial ETC in the skeletal muscle from obese 
individuals, compared to lean counterparts (53). This suggests a negative status of maintaining 
extra-mitochondrial ATP free energy by a low metabolic flux. Moreover, in the same paper, 
relative lower abundance of electron transfer chain complex I and enzymes related to BCAA 
metabolism were found in obese people (53). In addition, animal study reported that mice, 
develops obesity after 16 weeks of high-fat, high-sucrose diet feeding, showed lower ratio of 
mitochondrial DNA content versus nuclear DNA content, accompanied with decrease enzymatic 
activity of electron transport chain and mitochondria morphology, compared to its counterparts 
(12). Taken together, these results shows the activity of mitochondrial ETC is dysfunctional 
under obesity conditions in skeletal muscle (Figure 2.1B). 
Uncoupling proteins that are capable of uncoupling the proton gradient produced by ETC for 
ATP production, especially uncoupling protein 3 (UCP3), was firstly discovered in human 
skeletal muscle in 1997 (84). Inconsistent results of skeletal muscle UCP3 expression are 
reported between human and animal studies in obesity conditions. Two human studies showed 
no difference in UCP3 expression between lean and obese adults (52, 83). However, diet-induced 
obese mice showed decreased expression of UCP3 in skeletal muscle compared with normal 
diet-fed mice (25). After that, another study demonstrated transgenic mice that overexpressing 
human UCP3 had lower weight comparing with obese littermates even had higher food intake 
(18). In addition, mice overexpressing UCP3 showed improved glucose clearance and lower 
fasting plasma glucose and insulin level, which indicated enhanced glucose sensitivity (17). 
Similar research demonstrated in vivo overexpression of UCP3 in skeletal muscle protected mice 
being obese and insulin resistant from high-fat-diet feeding (17). The discrepancy in the 




explained by species difference. Therefore, further study on comparing UCP3 expression and 
protein content in skeletal muscle between lean and obese adults is needed (Figure 2.1B). 
2.3.4 Autophagy & ubiquitin proteasome system 
 Autophagy is activated when misfolded proteins or damaged organelles accumulate 
intracellularly (54). During the process, proteins and/or organelles are first engulfed in 
autophagosome that then fuses with lysosomes to degrade the engulfed material for the purpose 
of energy recycle for other cell metabolism-related pathways. Therefore, autophagy plays a key 
role in protein turnover, especially protein breakdown. Reports on the changes in autophagy in 
skeletal muscle taken from obese conditions are inconsistent. It is reported that in female rats fed 
with high-fat diet for 16 weeks, there is no alternation in the indicators of autophagy such as 
microtubule-associated protein 1A/1B-light chain3 (LC3) lipidation and protein content of 
Beclin1 and Atg7 in the soleus and plantaris muscle, accompanied with no alternation in 
lysosomal enzyme activity (16). Our previous in vitro study also demonstrates no alternation in 
protein content of p62 and lipidated LC3 in palmitate-treated C2C12 myotubes (91). However,  
another study using primary human skeletal muscle cells from lean and obese people, showed 
slower autophagic/lysosomal flux and lower expression of autophagy-related genes such as 
autophagy-related gene 4B (ATG4B) and gamma amino butyric acid receptor associated protein 
(GABARAPL-1) in skeletal muscle cells from obese patients (11). Similarly, Fan and Xiao 
showed higher autophagy flux indicated by higher LC3 lipidation and autophagosome formation 
in diet-induced obese mice (28). This could be explained by different models used, primary cell 
culture versus animal model. Taking these results together, it is apparent that autophagy is 




investigation is needed for better understanding how autophagy alters in skeletal muscle of obese 
patients. 
 Ubiquitin proteasome system (UPS) is another major intracellular mechanism for protein 
breakdown. Briefly, the whole process includes five steps: 1) Attachment of ubiquitin to 
ubiquitin activating enzyme (E1); 2) Transfer of ubiquitin to ubiquitin conjugase (E2); 3) 
conjugation of ubiquitin within substrate through ubiquitin ligase (E3); 4) formation of 
polyubiquinated substrate; 5) degradation of substrate by 26S proteasome and release of 
ubiquitin. In skeletal muscle, there are two muscle-specific E3 ligases are identified, Atrogin1 
(35) and MuRF1 (10). Skeletal muscle cells taken from obese patients have higher proteasome 
enzyme activity under starving condition than lean counterparts, and higher expression of 
FOXO3, a transcription factor for Atrogin1 and MuRF1 (11) (Figure 2.1C). In the skeletal 
muscle of mice fed with high-fat diet, expressions of Atrogin1 and MuRF1 are higher than mice 
fed with control diet (1). However, there is still a lack of research in how UPS is dysregulated 
under obesity conditions. 
2.3.5 Fat Metabolism 
 In skeletal muscle, fat deposition can be divided into two categories: extramyocellular 
lipid (EMCL) and intramyocellular lipid (IMCL). EMCL and IMCL, measured by nuclear 
magnetic resonance (NMR) spectroscopy, are higher in the tibialis anterioris muscle of 
overweight and obese men, and are positively correlated with abdominal fat (24). Another study 
also showed increased IMCL and EMCL in overweight and obese men, and an increase in 
IMCL-to-creatine ratio as BMI increases (82). The cause for this could be dysregulations in both 




 Normal weight men that were fed a high-fat diet for 5 days showed lower fatty acid 
oxidation rate and lower fatty acid suppressibility of pyruvate oxidation in the skeletal muscle, 
with an increased in serum free fatty acid acids (FFAs) (13). This study suggests that the 
elevated level of serum FFAs might correlated with lower fatty acid oxidation. In addition, total 
lipid catabolism is shown decreased in skeletal muscle cells taken from obese patients (49). 
Consistent with this finding, it is shown that a trend of decrease found in the expression of 
carnitine palmitoyltransferase 1 (Cpt1), the rate-limiting step in the transport of fatty acids into 
mitochondria for oxidation, in the skeletal muscle of female Cynomolgus Macaques fed with 
Western diet (36). In mice, it is reported that phosphorylation acetyl-CoA carboxylase (ACC) by 
AMP kinase (AMPK) is necessary for fatty acid oxidation in the skeletal muscle (67). ACC is 
involved in the synthesis of short chain fatty acids, and is inhibited by its phosphorylation. It is 
confirmed by in vitro study that phosphorylation of ACC is decreased in palmitate-treated 
C2C12 myotubes (76). These reports suggests a potential higher fatty acid synthesis in the 
skeletal muscle under obesogenic conditions. In genetic obese animal model, ob/ob mice, there is 
higher content of long chain fatty acids such as 16:0, 18:1, and 18:0 triacylglycerol, and higher 
expression of fatty acid elongase in the skeletal muscle (41). Previous animal studies from our 
lab also demonstrated higher gene expression of fatty acid synthase (FAS) in skeletal muscle of 
obese Zucker rats comparing with lean controls (30). Overall, higher fatty acid synthesis and 
lower fatty acid oxidation signals are possible factors contributing to the development of both 





2.4 The effect of leucine on different pathways in obese muscle 
Healthy diets benefits obese patients in multiple aspects. For example, consuming a high 
protein diet for 12 weeks in overweight and obese women showed a significant reduction in body 
weight, in which fat mass was reduced and lean mass was maintained (63). In addition to weight 
loss and reduced adiposity, obese patients who consumed a high protein diet for 12 weeks 
showed improved profile of cardiovascular diseases with elevated triacylglycerol (20). High 
protein supplementation also benefits weight loss and lean mass preservation in obese patients 
(31). High protein diet or high protein supplementation contains substantial amount of branched-
chain amino acids (BCAA), valine, isoleucine, and leucine. Among valine, isoleucine, and 
leucine, leucine has been shown to activate mTORC1 pathway to increase protein translational 
initiation in muscle (3). Therefore, it is interesting to understand whether dietary leucine 
supplementation would improve obesity and muscle function. The sections below summarize 
current evidence on the mechanisms involved in the effect of leucine supplementation on obese 
muscle.  
2.4.1 Leucine improves obesity through activating mTORC1 signaling in muscle 
Leucine upregulates protein synthesis in muscle through promoting mTORC1 signaling. 
Previously, the effect of leucine supplementation on improving muscle function has been 
reported in cell studies (48), animal studies (22) and human studies (31). Therefore, researchers 
started to hypothesize whether leucine can improve obesity-related skeletal muscle dysfunctions 
through mTORC1 signaling. Dietary supplementation of leucine in drinking water for mice fed 
with high-fat diet showed reverse effect on metabolic abnormalities such as glucose tolerance, 
hepatic steatosis, adipose tissue inflammation. Moreover, leucine caused upregulation in 




molecule of mTORC1(62). Another study showed that chronic leucine supplementation 
improves insulin sensitivity and reduced oxidative stress, accompanied by stimulation in 
mTORC1 signaling in skeletal muscle (58). In addition, central administration of leucine in 
hypothalamus stimulates mTORC1 signaling and decreases food intake and body weight in rats 
(21). In human studies, whey protein supplement enriched in leucine appears to increase fat mass 
loss and prevent more lean muscle mass loss in obese people, compared to normal weight 
counterparts (31). Notably, sestrin2 was shown to be a sensor for leucine to activate mTORC1 
intracellularly (90). However, in human muscle, sestrin2 was not hyper-phosphorylated by 
ingestion of a milk protein concentrate (95). Another study showed leucyl-tRNA synthetase is an 
intracellular leucine sensor for mTORC1 activation (40). To our knowledge, the only evidence 
for the role of leucyl-tRNA synthetase in muscle is its involvement in C2C12 myoblast 
differentiation (71). Thus, it is unclear what the intracellular leucine sensor in muscle is. The role 
of mTORC1 signaling in promoting protein synthesis rate in skeletal muscle has been 
emphasized (Figure 2.2A). However, there is still a deficit in the amount of investigation about 
the effect of leucine supplementation or protein supplementation that high in leucine on 
upregulating protein synthesis through mTORC1 signaling in obese patients. 
2.4.2 Leucine improves obesity through mitochondria in muscle 
In obesogenic conditions, especially in skeletal muscle, an organism heavily dependent on 
oxidative phosphorylation, mitochondrial dysfunctions are common (50). The positive effect of 
leucine supplementation on mitochondrial function has been reported in cell (72) and animals 
(46). In mouse myotubes cell model, C2C12, 24h leucine treatment led to increased 
mitochondrial content, which is related to upregulated mitochondrial biogenesis genes, PPARβ/δ, 




to induce obesity-linked dysfunctions in vitro (91). Previous study from our lab also showed 
increased mitochondrial contents in leucine-supplemented palmitate-treated C2C12 myotubes 
(91). In addition, mitochondrial function-related genes (e.g. nuclear respiratory factor 1 (NRF1) 
and ATP synthase) are upregulated by dietary leucine supplementation in piglets (46). Based on 
the protective effect of leucine supplementation on mitochondrial function, biogenesis and gene 
expression, researchers considered whether the positive effect caused by leucine supplementation 
in obesity is related to improved mitochondrial function. In high-fat diet-induced obese mice, 
leucine supplementation reduces fat mass, which is correlated with upregulation of mitochondrial 
metabolism gene, PGC1α (56). Another study showed that leucine supplementation improve 
mitochondrial biogenesis, revealed by enhanced mitochondrial DNA copy number, increased 
protein content of oxidative phosphorylation complex I to IV, augmentation in serum ATP 
content at the stage of hyperglycemia (60). More recently, leucine supplementation increases 
intermyofibrillar, not subsarcolemmal, mitochondrial size in diet-induced obese mice (14). 
Conclusively, leucine has been shown to improve mitochondrial function, quality, and number in 
skeletal muscle that under obesogenic conditions (Figure 2.2B).   
2.4.3 Leucine improves obesity through protein breakdown-related signaling in muscle 
The interaction between leucine and autophagy has been reported in human embryonic 
kidney 293 (HEK293T) cells (92). Increased signal of autophagy, present by higher LC3 
lipidation and p62 protein content, is observed in leucine-deprived cells (92). In addition, leucine 
supplementation reduces Barkor puncta formation, an indicator for autophagosome formation, in 
vivo (92). Low-protein diet-induced elevation in triglyceride accumulation, a common 
phenomenon happens during the development of obesity, was shown restored by leucine 




reduced in leucine supplemented low-protein diet-fed group (93). The low-protein diet used in 
this study does not completely simulate diet-induced obesity. High-fat diet or Western diet is 
suggested to be used for further investigation on the mechanism of leucine supplementation on 
autophagy in skeletal muscle. 
The anti-atrophy effect of leucine on skeletal muscle through prevention of expression of 
MuRF1 and Atrogin-1, which play essential role in skeletal muscle atrophy, was shown by 
Baptista et al (4). Furthermore, Rasmussen et al reported higher muscle fractional synthesis rate 
in a high leucine consumption (3.5g leucine) group of young men and women comparing with a 
typical high quality protein consumption (1.8g leucine) group of young men and women, 
although no changes were detected in ubiquitin-proteasome system between two groups (34). 
However, the supplementation used in this study is high quality protein, not single leucine 
supplementation, which the effect of leucine could be blunted by other amino acids. It is still of 
interest in investigating the effect of leucine supplementation on protein degradation pathways 
such as autophagy and UPS in skeletal muscle under diet-induced obesity conditions. A 
schematic diagram of the action of leucine on autophagy and UPS in skeletal muscle under 
obesity condition can be found in Figure 2.2C. 
2.4.4 Leucine improves obesity through fat metabolism in muscle  
 Leucine supplementation is shown to increase phosphorylation level of ACC in skeletal 
muscle of high-fat diet fed mice (55). This indicates leucine supplementation might be able to 
block fatty acid synthesis. In addition, overweight and obese people consuming a dietary 
supplementation containing 750 mg leucine showed increased fat oxidation rate (94). Consistent 
with these results, in vitro study from our lab also showed leucine reduces IMCL and upregulates 




results showing branched-chain amino acid (BCAA) restriction increases fatty acid oxidation in 
skeletal muscle of obese Zucker rats (85). This could be explained by the difference in the 
experimental models used. Obese Zucker rats has a mutated leptin receptor leading to 
hyperphagia, which is different mechanistically with high-fat diet-induced obesity. 
Summarization of the effect leucine on fat metabolism in skeletal muscle under obesity condition 
is shown in Figure 2.2D. Apparently, there are two major problems needed to be addressed in the 
future: 1) impairments in leucine catabolism in skeletal muscle under obesogenic conditions; 2) 




The mechanism underlying the effect of leucine on skeletal muscle under obese 
circumstance is present in Figure 1.2. Leucine, as a well-known activator of mTORC1 pathway, 
has been shown to improve obesity-related phenotypes (31, 57). In addition, leucine 
supplementation is shown to promote mitochondrial biogenesis (45) and mitochondrial size (59) 
in skeletal muscle of obese models. As a result, increased ETC enzymes activity (59) and ATP 
production (45) are observed. Autophagy signal, present by LC3 lipidation, is also decreased by 
leucine supplementation in skeletal muscle, which suggests a decrease in protein degradation 
(93). Lastly, leucine supplementation is present to decrease fatty acid synthesis through 
inhibiting ACC activity (55) and increase fatty acid oxidation through upregulating Cpt1 
expression (91) in skeletal muscle of obese models. 
Elevation of plasma BCAAs is commonly seen in obese models, and studies have suggested 




mitochondrial branched chain amino acid aminotransferase (BCATm) and branched chain α-keto 
acid dehydrogenase (BCKDH, E1α subunit) complex, in the omental and subcutaneous fat 
tissues, not liver or muscle, may contribute to the rise in plasma BCAAs (75). Same group of 
researchers show that by knocking out BCATm globally, mice fed with high-fat diet are 
significantly resistant to obesity (74). In addition, adipose tissue, not muscle, is suggested to 
regulate circulating BCAAs level in in vivo (42). Recently, one study using diet-induced insulin 
resistant animal model shows impaired skeletal muscle BCATm activity, while adipose tissue 
BCATm remains unchanged (23). Moreover, they find higher phosphorylation of BCKDH only 
in skeletal muscle of insulin resistant animals (23). Therefore, we suggest more studies related to 
the mechanisms of adipose tissue-skeletal muscle crosstalk with leucine supplementation under 
obesogenic conditions should be carried out in the future. 
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Figure 2.1. Schematic pathways dysregulated by obesity in skeletal muscle. Summary of current 
evidence on dysregulated pathways related to muscle protein turnover and energy metabolism in 
obesity condition. (A) Decreased muscle protein synthesis rate could be a result of blunted 
mTORC1 activation in obesity condition; (B) Obesity decreases electron transport chain activity, 
and UCP3 expression possibly, to cause decreased ATP production and accumulated reactive 
oxygen species in skeletal muscle; (C) Obesity increases protein degradation through LC3 
lipidation-mediated autophagy and FOXO3-mediated ubiquitin proteasome system in skeletal 
muscle; (D) Obesity increases extramyocellular and intramyocellular lipids through decreasing 
Cpt1-regulated fatty acid oxidation and ACC and FAS-regulated fatty acid synthesis. Figure 






Figure 2.2. Possible mechanisms underlying the effect of leucine supplementation for improving 
skeletal muscle in obesity. This scheme encapsulates current evidence on possible mechanism 
involved in effect of leucine supplementation in skeletal muscle and subsequent physiological 
consequences. (A) Leucine activates mTORC1 pathway to promote protein synthesis for 
prevention of muscle loss in obesity, while the role of leucine sensor, leucyl-tRNA synthetase, is 
unclear; (B) Leucine promotes mitochondria production through increasing expression of 
mitochondrial biogenesis-relate genes such as PGC1α, PPARγ, NRF1, PPARβ/δ, and increases 
mitochondrial size through unknown pathway, to increase ATP production in obese muscle; (C) 
Leucine reduces LC3 lipidation to decrease autophagy signal, and reduces ubiquitin-proteasome 
system possibly through inhibiting Atrogin1 and MuRF1 expression, to downregulate protein 
degradation in obese muscle; (D) Leucine decreases intramyocellular lipid and extramyocellular 
lipid through upregulating carnitine palmitoyltransferase 1-mediated fatty acid oxidation, and 
through inhibiting acetyl-CoA carboxylase-mediated fatty acid synthesis. Figure is drawn by 









Age-related sarcopenia continues to exacerbate life quality of elderly in the United States. 
Continuous loss of skeletal muscle mass leads to higher risk of disability and death in elderly. 
This could be imbalances in muscle protein kinetics and energy metabolism. Thus, the first 
objective of this review was to summarize current evidence showing dysregulated molecular 
pathways involved in muscle protein kinetics and energy metabolism in aging conditions. 
Leucine is well-known as the activator of the mechanistic target of rapamycin complex 1 
(mTORC1) pathway, which plays a central role in mediating muscle protein synthesis. 
Therefore, the second objective of this review was to summarize current evidence showing the 
effects of leucine on molecular pathways related to muscle protein kinetics and energy 
metabolism in aging conditions.  
 
3.2 Introduction 
In 2015, 9 percent of total world population, 617 million were aged 65 and older. It was 
estimated that the older population will be approximately 1 billion by 2030, and 1.6 billion by 
2050 (47). Older adults suffer continuous skeletal muscle loss, also known as age-related 
sarcopenia. The most direct consequence of skeletal muscle loss is falling down that leads to 
other injuries; e.g. bone breakage. It is shown that one out of four older adults falls each year in 
the United States (38). Falls can cause non-fatal injuries such as hip fractures, cataclasis, head 
trauma, and would lead to death in older adults (3). It cost the whole nation $50 billion a year to 




treating falls in the older adults would be $101 billion in 2030 if the rates of falls are not reduced 
(19).  
 There are two factors contribute to poor physical performance in the older adults: skeletal 
muscle loss and dysregulated fat deposition. Further, skeletal muscle loss is suggested to be 
caused by higher muscle protein degradation rate and lower muscle protein synthesis rate (46, 
48). Dysregulated fat deposition can be the results of increased fat infiltration (45) and fat 
accumulation (14). There are a variety of components in different pathways identified to be 
involved in age-related sarcopenia and fat deposition dysregulation. Therefore, the first objective 
of the present review is to summarize current evidence in determining the role of multiple 
pathways in the development of sarcopenia and higher fat deposition in the skeletal muscle of 
older adults. 
 Leucine has been shown to activate the mechanistic target of rapamycin complex 1 
(mTORC1) pathway, which is the main regulator for protein synthesis in the skeletal muscle (1). 
Activation of mTORC1 pathway was also shown to inhibit protein degradation-related pathways 
such as autophagy (55) and ubiquitin proteasome system (UPS) (27) in muscle. Thus, there are 
substantial studies have been done to reveal the effect of leucine supplementation on autophagy 
and UPS in aging muscle. However, the effect of leucine supplementation on fat deposition and 
related mechanism in aging muscle is still unclear. Therefore, the second objective of the present 
review is to summarize mechanisms including mTORC1, autophagy, UPS, and fatty acid 






3.3 Dysregulated pathways underlying aging muscle 
3.3.1 mTORC1 
 The mTORC1 pathway was shown to be less activated in the skeletal muscle of older 
adults, as revealed by lower relative phosphorylation level of mTOR, S6 kinase 1 (S6K1), and 
eukaryotic initiation factor 4E binding protein 1 (4EBP1), than young counterparts after 6 h of 
exercise (17). In addition, muscle fractional synthesis rate was shown to increase to a lower 
extent in the muscle of older adults (17). Similar impairments in the relative activation of 
mTORC1 pathway after a bout of resistant exercise were reported in the muscle of older adults 
(16). It is interesting to point out that the relative phosphorylation of mTORC1 pathway were not 
different in the skeletal muscle from young and old adults in these two studies (16, 17). 
However, in another recent animal study, it is shown that relative phosphorylation of mTORC1 
pathway at baseline was higher in the skeletal muscle (11). The discrepancy could be explained 
by the different muscle samples used. In the animal study, soleus muscle, a typical type I fiber, 
was used. While in the two human studies, vastus lateralis, was used. Vastus lateralis muscle in 
human is consist of type I and type II fiber, and the number and size of type II fiber was shown 
to decline in the older adults (6). However, another study showed no difference in muscle 
fractional synthesis rate between young and old adults, and higher absolute phosphorylation 
levels of mTORC1 pathway in the vastus lateralis muscle of older adults (25). Similar to this 
result, absolute phosphorylation level of S6K1, not mTORC1, was observed in the vastus 
lateralis muscle from older adults (37). Notably, in these two study, they only measured the 
absolute phosphorylation level of mTORC1 and its components, which did not reflect the true 





Autophagy is a cellular process in which damaged cellular components such as misfolded 
protein and organelles are transported to lysosomes for degradation. Autophagy can be 
categorized into three kinds: macro-autophagy, micro-autophagy, and chaperone-mediated 
autophagy (CMA). The discussion below will focus on macro-autophagy.  Briefly, autophagy 
has three stages: 1) Formation of autophagosome; 2) Fusion of autophagosome; 3) Degradation 
of the materials in lysosome. Therefore, autophagy has been suggested to facilitate protein 
degradation in aging muscle. For examples, expression of Beclin1, a protein involved in 
initiation of autophagosome formation, and p62, a protein involved in autophagosome formation, 
were found upregulated in the vastus lateralis muscle of older adults (53). In human studies, 
higher protein content of Beclin1 was found in the plantaris muscle of aged rats (50). However, 
protein content of autophagy-related gene 7 (ATG7) and autophagy-related gene (ATG9), which 
are involved in autophagosome formation, and microtubule-associated protein 1 light chain 3 
(LC3) lipidation, which is an autophagosome marker, were found unchanged in the muscle of 
aged rats (50). Data from our lab found higher expression of p62, ATG7, and Beclin1 in the 
vastus lateralis muscle of older adults (unpublished data). However, in animal studies, the results 
are inconsistent. Higher protein content of p62 and lower LC3 lipidation were reported in the 
muscle of aged (27-month-old) mice (56). Meanwhile, protein content of ATG5-ATG12 
conjugate, which is necessary for LC3 lipidation, was found lower in the aged murine muscle 
(56). Another animal study used young (3-month-old) and aged (24-month-old) mice showed 
higher accumulation of cytosol Beclin1 and p62 in the quadriceps muscle of aged mice, while 
content of Beclin1 and p62 in nucleus and membrane were unchanged (34). Overall, the 




consequence of species characteristics. Furthermore, there could be a balance in the flux of 
autophagy, as proper activation of autophagy was shown to be necessary for maintaining muscle 
mass (26). Thus, understanding of the balance between proper-activation and over-activation of 
autophagy is needed for future study in aging muscle. 
3.3.3 Mitochondria 
 Mitochondria is the powerhouse that produce ATP for all cellular process. In muscle, 
ATP generated by mitochondria enable muscle to contract and move. Mitochondrial capacity or 
functio are reported in turns of numbers, sizes, electron transport chain (ETC) complexes 
enzymatic activity, and so on. Muscle taken from human undergoing exercise training had 
multiple improvements in mitochondria such as bigger mitochondrial size (29). In addition, 
muscle-specific knockout of mitofusins, which are important for mitochondria fusion, in mice 
significantly decreased muscle performance (7). In aging adults, there were lower mitochondrial 
ATP production and lower mitochondrial DNA copy number in the skeletal muscle taken from 
older adults (22). In addition, mitochondrial bioenergetics revealed by cytochrome c oxidase 
(COX) enzymatic activity was shown in the skeletal muscle of older adults, accompanied with 
lower protein content of mitochondrial biogenesis markers, peroxisome proliferator-activated 
receptor gamma coactivator 1 alpha (PGC-1α) (21). Changes in mitochondrial morphologies 
such as lower mitochondrial number and decreased mitochondrial size revealed in the 
subsarcolemmal component were observed in the skeletal muscle of older adults (12). 
Mitochondrial dysfunction was suggested to contribute to the programmed cell death of skeletal 
muscle in aged mice, as necrosis was found to be predominant in atrophic and morphologically 




been shown to be abnormal in multiple aspects, and the abnormalities further contribute to the 
death of muscle fibers to exacerbate poor muscle performance.   
3.3.4 Fat Metabolism 
 Significant increased fat deposition, especially intermuscular fat infiltration, was found in 
the gastrocnemius medialis and soleus muscle of older adults (13). This could result from 
decreased fatty acid oxidation (44) and increased fatty acid synthesis (43) in aging muscle. On 
the side of fatty acid oxidation regulation, there are two major enzymes, carnitine 
palmitoyltransferase I (Cpt1) for β-oxidation of long chain fatty acids (LCFAs), which is 
localized at the outer membrane of mitochondria; and Cpt2 for  β-oxidation of medium chain 
fatty acids (MCFAs), which is localized at the inner membrane of mitochondria. Skeletal muscle 
specific isoform of Cpt1, Cpt1b, knockout in middle-aged mice showed impaired LCFAs 
oxidation and increased intramyocellular lipid (IMCL) accumulation (49). Primary myotubes 
taken from Cpt2 deficient patients showed higher content of C16:0 acylcarnitines and lower fatty 
acid oxidation flux (8). However, there is no direct evidence showing deficiencies of Cpt1 or 
Cpt2 in aging muscle. On the side of fatty acid synthesis, activity of acetyl-CoA carboxylase 
(ACC), which catalyzes the step to provide malonyl-CoA for fatty acid synthesis, was found 
increased in vastus lateralis muscle of older adults (23). 
 
3.4 Pathways involved in leucine supplementation-mediated beneficial effects on aging 
muscle 
3.4.1 mTORC1 
Leucine supplementation increases muscle protein synthesis through activating mTORC1 




showed short-term (4 days) leucine supplementation increased muscle fractional synthesis rate 
(FSR) (32). However, they did not measure how mTORC1 pathway was regulated by leucine 
supplementation. A later study demonstrated that chronic leucine supplementation (2 weeks) 
increased postabsorptive muscle FSR in older adults; at the same time, higher phosphorylation 
level of mTORC1, 4EBP1, and S6K1 were observed in vastus lateralis muscle from older adults 
supplemented with leucine (9). Inconsistent results were reported in animal studies. Long-term (6 
months) leucine supplementation did not alter mTORC1 pathway in gastrocnemius muscle from 
18-month-old rats and muscle mass (54). Another animal study showed leucine-enriched 
essential amino acid (EAA) mixture supplementation increased phosphorylation level of 
mTORC1 and muscle fiber size in aged rats (30). In this study, phosphorylation level of 4EBP1 
and S6K1 were not measured to verify true activation of mTORC1 pathway. Leucine 
supplementation also induces muscle hypertrophy and mTORC1 pathway activation in C2C12 
myotubes (2). Overall, leucine supplementation can increase muscle protein synthesis through 
activating mTORC1 pathway in muscle from aging adults; however, this is still unclear in aging 
animal models and cell models.  
3.4.2 Autophagy 
 Leucine supplementation is shown to reduce muscle protein degradation through 
suppressing autophagy signal as LC3 lipidation decreased after leucine supplementation in 
C2C12 myotubes (35). In animal, leucine supplementation was also found to increase muscle 
mass and inhibit autophagy signal (39). In dexamethasone-induced muscle atrophy animal 
model, leucine-enriched branched-chain amino acids (BCAA) supplementation reduced LC3 
lipidation in muscle (52). While in another study using dexamethasone-induced muscle atrophy 




addition, unchanged LC3 lipidation was reported in muscle from hindlimb suspended rats that 
supplemented with leucine-enriched BCAA (24). In the muscle atrophy models, it is still unclear 
if autophagy is involved in leucine supplementation-mediated muscle improvements. Further, 
some studies used leucine-enriched BCAA supplementation, instead of leucine supplementation, 
which did not completely prove the muscle beneficial effects were caused by leucine. More 
markers for autophagy such as autophagy-related genes (ATGs) expression, autophagosome 
morphology, lysosomal enzymatic activity, not just LC3 lipidation or LC3 expression. 
Additionally, there is no study conducted to investigate how autophagy is regulated by leucine 
supplementation in aging muscle.  
3.4.3 Mitochondria 
 In vitro, it is shown that leucine increased mitochondrial mass, oxygen consumption and 
expression of mitochondrial biogenesis-related genes including sirtuin1 (SIRT1), PGC-1α, and 
nuclear respiratory factor 1 (NRF1) in C2C12 myotubes (41). In animal model of aging, muscle 
mitochondrial COX activity was shown to be enhanced by leucine supplementation, while citrate 
synthase activity was not changed by leucine supplementation (18). From the in vitro and in in 
vivo studies, it is suggested that leucine could improve mitochondrial function and biogenesis in 
muscle cells and aging muscle. However, the current evidence in clinical trials are inconsistent. 
Leucine-enriched BCAA supplementation did not change mitochondrial ATP production and 
mitochondrial DNA copy numbers in vastus lateralis muscle from older adults (42). Similarly, 
ATP production in muscle from older adults consumed essential amino acid (EAA) 
supplementation deprived of leucine did not differ from adults consumed EAA supplementation 
containing leucine (28). Notably, the muscle cells used in previous mentioned in vitro study was 




DNA, which suggested lower expression of mitochondria-related proteins (31). Therefore, it is 
still unknown if leucine can improve mitochondrial function or biogenesis under aging 
conditions at in vitro level. In addition, more markers such as mitochondrial morphology and 
bioenergetics are needed to be verified for the effect of leucine supplementation on mitochondria 
in aging muscle. 
3.4.4 Fat Metabolism 
Leucine increases fatty acid oxidation in skeletal muscles (40). Sun et al showed 
increased fatty acid oxidation and expression of uncoupling protein 3 (UCP3) in C2C12 
myotubes (40). Leucine was also shown to increase the phosphorylation level of acetyl-CoA 
carboxylase (ACC), an enzyme involved in fatty acid synthesis, which suggested a lower level of 
fatty acid synthesis (4). Inconsistent results are reported in in vitro study (36). For example, 
increased gene expression of fatty acid synthase (FAS) and cellular lipid content were found in 
C2C12 myotubes treated by leucine (36). In addition, lipid content measured by oil red o staining 
was increased by leucine treatment (33). However, another study reported reduced lipid content 
in C2C12 myotubes treated by both palmitate and leucine (20). In vitro study from our lab also 
showed leucine decreased intracellular lipid droplets in palmitate-treated C2C12 myotubes (51). 
Notably, these studies all showed increased mitochondria biogenesis and function-related gene 
expression. As Cpt1 localizes on the outer membrane of mitochondria, mitochondria is also 







 Impaired pathways involved in compromised muscle performance and reduced muscle 
mass in the aging population is well-studied. In addition, effect of leucine supplementation on 
increasing muscle protein synthesis through mTORC1 pathway is also well-recognized. 
However, the role of protein breakdown-related autophagy pathway, mitochondrial pathway and 
related fat metabolism are less studied. Therefore, it is necessary to understand whether these 
pathways are regulated by leucine supplementation in muscle under aging conditions. 
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4 Chapter 3. Differential Gene Expression of Autophagy, Mitochondrial Biogenesis and 
Fat Metabolism in Skeletal Muscle of Overweight and Obese Adults, and Relationship 
with Whole Body Protein Kinetics 
 
4.1 Abstract  
Obesity prevalence keeps increasing in the United States. One of the consequences of obesity on 
the skeletal muscle is poor physical performance and reduced relative muscle mass. Reduced 
skeletal muscle physical performance will result in poor life quality of obese population. 
Therefore, the first objective of this study was to compare the gene expression related to 
autophagy, the ubiquitin proteasome system, mitochondrial biogenesis, and fat metabolism 
between normal weight and overweight and obese adults. The second objective was to determine 
if there was a correlation between whole body protein kinetics and gene expression in individuals 
of different BMI. RT-qPCR was used to determine the relative fold change of targeted genes in 
the skeletal muscle of overweight and obese adults. We then performed hierarchical regression 
analysis to determine if BMI had a moderating effect on the correlation between expression of 
targeted genes and whole body protein kinetics. We found an increase in expression of 
autophagy-related genes, ATF4, GADD45A, ATG3, ATG5, ATG7, Beclin1, LC3B, p62, 
ubiquitin proteasome system-related gene, MuRF1, mitochondrial biogenesis-related genes, 
NRF1, PGC1α, Tfam, UCP2, and fat metabolism-related genes, ACC, PPARα, SREBP1, 
FATP1, FATP4, in the overweight and obese adults. In addition, decreases in the expression of 
ubiquitin proteasome system-related gene, Atrogin1, and mitochondrial biogenesis-related gene, 
PPARγ, were observed in the overweight and obese adults. Hierarchical regression analysis 
revealed that there was no significant correlation between expression of target genes and whole 





According to the Centers for Disease Control, approximate 42.4% of adults in the United 
States are obese (15). Over-accumulation of fat in obese patient disrupts body composition 
resulting in a decreased skeletal muscle to body fat ratio (25) resulting in decreased skeletal 
muscle physical performance (17). For example, obese adults with higher intermuscular lipid 
content have decreased leg muscle strength, muscle power, and modified physical performance 
test scores (17). Whole body protein turnover balance affects skeletal muscle mass. It has been 
demonstrated that obese adults have higher protein breakdown and protein synthesis rates 
compared to normal weight adults, however overall net balance remained unchanged between 
normal weight and obese adults (5) (11).  There are two pathways largely studied for the 
regulation of protein breakdown, autophagy and the ubiquitin proteasome system (UPS).   
Autophagy is activated when damaged cellular organelles and misfolded proteins are 
accumulated intracellularly. Increased autophagy flux is reported in the primary skeletal muscle 
cells taken from obese adults compared with lean adults (2). In addition, autophagy signaling is 
found upregulated in skeletal muscle of diet-induced obese mice (28). Expression levels of the 
autophagosome marker, microtubule associated protein 1 light chain 3 beta (LC3B), and central 
autophagy regulator, Beclin1, are upregulated in the skeletal muscle of diet-induced obese mice 
(28). Regarding to UPS, proteasome activity is shown to be higher in the primary skeletal muscle 
cells taken from obese adults compared with lean adults (2). UPS signals in muscle are also 
shown upregulated in skeletal muscle of obese mice (1). Two muscle-specific UPS E3 ligases, 
Atrogin1 and MuRF1, were upregulated in the muscle of diet-induced obese mice, and a higher 




However, there is gap in how expression of markers of autophagy and UPS change in skeletal 
muscle of obese adults. 
Energy metabolism in skeletal muscle relies heavily on ATP produced by mitochondria. 
Mitochondrial dysfunction in skeletal muscle occurs with obesity in adults (20). For example, 
There is lower activity of complex I, a component of the electron transport chain, and 
mitochondria size in the skeletal muscle of obese subjects compared to lean adults (20, 33). In 
recent years, there has been accumulating evidence demonstrating impaired mitochondrial 
function in skeletal muscle of rodent models of diet-induced obesity (16, 18). For example, 
decreased expression of (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) 
PGC1α, a transcription factor regulating mitochondrial biogenesis, was found in skeletal muscle 
from mice fed with high-fat diet for 8 weeks compared with mice fed with control diet for 8 
weeks (18). Further, smaller intermyofibrillar mitochondrial size has also observed in the mice 
fed with high-fat diet for 4 weeks compared with mice fed with a control diet for 4 weeks (16).  
Energy metabolism is also affected by balance between fat oxidation and fat synthesis. 
Individuals with obesity have increased fat accumulation surrounding and within skeletal muscle 
(14). This could be due to a decrease in fatty acid oxidation observed in the skeletal muscle from 
obese adults (24) or a decrease in expression of carnitine palmitoyltransferase 1 (Cpt1), the 
enzyme that catalyzes the first rate-limiting step of fatty acid oxidation (30). In addition, there is 
upregulated fat synthesis-related enzyme, stearoyl-CoA desaturase-1, expression in skeletal 
muscle of obese adults compared with lean adults (19). However, the gene expression related to 
fat metabolism in skeletal muscle of obese adults are unknown. 
Therefore, the first objective of this study was to determine differences in gene 




between normal weight and overweight/obese adults. Our second objective was to determine 
whether BMI has a moderating (enhancing or buffering) effect on the correlation between gene 
expression and whole-body protein kinetics: protein synthesis rate (PS), protein breakdown rate 
(PB), and net protein balance (NB). 
 
4.3 Materials and Methods 
4.3.1 Participants and skeletal muscle biopsies 
In the present study, human vastus lateralis muscle biopsies were collected from two 
previously published studies, and muscle biopsies collected at fasted state were used for this 
study (21, 22). Briefly, forty two healthy participants including ten normal weight (NW, defined 
by BMI < 25 kg/m2), thirty one overweight and obese (OW/OB, defined by BMI ≥ 25 kg/m2) 
were recruited from the Little Rock area using local newspaper advertisements and flyers posted 
around the University of Arkansas for Medical Sciences campus and the Little Rock area. 
Written informed consent was obtained from all participants, and both studies were approved by 
the Institutional Review Board at the University of Arkansas for Medical Sciences. Exclusion 
criteria are described in published studies (21, 22). Characteristics of all participants are shown 
in Table 4.1. 
4.3.2 Stable isotope infusion and determination of whole body protein kinetics calculations 
The detailed protocol for tracer infusion and whole body protein kinetics are described in 
previous published studies (21, 22). Briefly, after an overnight fast, a baseline blood sample was 
taken to determine the background isotope enrichments. Primed continuous infusion of L-2H5-




(PS), protein breakdown (PB), and net balance (NB). A prime dose of L-2H4-tyrosine was 
injected to reach isotopic equilibrium of L-2H4-tyrosine enrichment derived from L-2H5-
phenylalanine infusion. Plasma was processed before determining the enrichments of 
phenylalanine and tyrosine. The detailed procedure was described in published study (21). Gas 
chromatography-mass spectrometry (GCMS) was used for the determination of enrichments of 
phenylalanine and tyrosine. Rate of appearance (Ra) into the plasma of phenylalanine and 
tyrosine and the fractional Ra of endogenous tyrosine converted from phenylalanine were used 
for whole body protein kinetics calculations, details and equations were previously described 
(21, 23).  
4.3.3 Real-time quantitative PCR 
Muscle RNA were extracted using TRIzol (Invitrogen, Waltham, MA), according to the 
manufacturer protocol. Next, a Roche Lightcycler 480 system (Roche, Indianapolis, IN) was 
used to synthesize cDNA based on the RNA concentrations following the manufacturer 
instructions. A reporter dye that specifically binds to double-stranded DNA, SYBR green 
(Quanta, Gaithersburg, MD) was used for the relative quantification of gene expression. Forward 
and reverse primers for all genes were designed by using Primer-BLAST from the National 
Center for Biotechnology Information (NCBI, Bethesda, MD). All primer sequences are 
provided in the supplementary table (supplementary table). Genes tested are: nucleoporin 62 
(p62), nucleoporin 53 (p53), autophagy related 3 (ATG3), autophagy related 5 (ATG5), 
autophagy related 7 (ATG7), Unc-51 like autophagy activating kinase 1 (ULK1), Beclin1, 
Atrogin1, and muscle RING-finger protein 1 (MuRF1), microtubule-associated proteins 1A/1B 
light chain 3B (LC3B), Peroxisome proliferator-activated receptor gamma coactivator 1-alpha 




receptor-gamma (PPARγ), transcription factor A mitochondrial (Tfam), uncoupling protein 2 
(UCP2), carnitine palmitoyltransferase I (Cpt1), acetyl-CoA carboxylase (ACC), fatty acid 
transporter 1 (FATP1), fatty acid transporter 4 (FATP4), peroxisome proliferator-activated 
nuclear receptor-alpha (PPARα), sterol regulatory element binding transcription factor 1 
(SREBP1). 18S ribosomal RNA (18S) was used as an internal reference. All primers were 
ordered from Integrated DNA Technologies (Coralville, IA) and primer sequences are provided 
in Table 4.6. All samples and controls were analyzed in duplicate. Fold change of target genes of 
overweight + obese group versus normal weight group were determined using 2-ΔΔCt method 
(29). 
4.3.4 Statistical analysis 
Multiple t test was used for comparing the difference between normal weight and OW/OB 
groups. Holm-Sidak method was used for correcting multiple comparison. Statistical analyzes 
were performed and figures were plot in Graphpad Prism, version 6 (San Diego, CA, USA). 
Hierarchical linear regression analysis was performed to test whether AGE moderated the 
association between mRNA and whole-body protein synthesis, protein breakdown, or net-
balance. In step 1, a control variable (Age) was entered to examine its influence on the dependent 
variables (PS, PB, and NB). In step 2, independent variables (mRNAs) were included to examine 
the influence of the independent variables on the dependent variable while controlling with the 
control variable. In step 3, a moderating variable (BMI) was included to examine whether the 
moderator variable can have a moderating effect on the dependent variable in the relationship 
between the dependent variable and the independent variable. Lastly in step 4, all two-way 
interactions (BMI x mRNAs) were introduced to examine whether the moderator variable can 




variable. In steps 2, 3, and 4, it was considered statistically significant when the delta F p-value 
was less than 0.05 and delta R2 increased stepwise. Results of step 1, 2, and 3 are shown in the 
supplementary tables. Statistical analyzes were performed using IBM SPSS statistics, version 23 
(Chicago, IL, USA). All significance level was set at 0.05 (α = 0.05). All p values that lower than 
0.05 were considered as significant. 
4.4 Results  
4.4.1 Whole body protein kinetics 
In Figure 4.1, there was no significant difference in PS, PB, and NB between and within 
NW and OW/OB group. 
4.4.2 Autophagy gene expression and effect of BMI on correlation with whole body protein 
kinetics 
As shown in Figure 3.2, expression of ATG3 (p < 0.01), ATG7 (p < 0.0001), Beclin1 (p 
< 0.0001), LC3B (p < 0.0001), and p62 (p < 0.0001) were upregulated in the OW/OB group. 
There was no correlation between expression of autophagy-related genes and PS or PB, and BMI 
(Table 4.2). However,  negative correlations were found in correlations with NB in expression of 
ATF4 (β = -0.213, p = 0.021), GADD45A (β = -0.191, p = 0.037), ATG3 (β = -0.207, p = 0.023), 
ATG5 (β = -0.207, p = 0.024), ATG7(β = -0.194, p = 0.036), Beclin1 (β = -0.216, p = 0.019),  
and p62 (β = -0.205, p = 0.024) (Table 4.2). 
4.4.3 Ubiquitin proteasome system gene expression, and effect of BMI on correlation with whole 
body protein kinetics 
Atrogin-1 and MuRF1 expression did not differ between NW and OW/OB groups (Figure 
4.3). There was no significant correlation detected between expression of UPS-related genes and 




(β = -0.202, p = 0.029) and MuRF1 (β = -0.228, p = 0.016) (Table 4.3) and NB. There was no 
effect of BMI on these correlations. 
4.4.4 Mitochondrial biogenesis gene expression, and effect of BMI on correlation with whole 
body protein kinetics 
Expression of NRF1 (p < 0.0001) and UCP2 (p < 0.0001) were higher in OW/OB group 
compared to NW (Figure 4.4). There was no correlation between mitochondria biogenesis-
related genes and PS or PB (Table 4.4). Expression of NRF1 (β = -0.180, p = 0.049), PGC1α (β 
= -0.235, p = 0.009), Tfam (β = -0.217, p = 0.016) were negatively correlated with NB (Table 
4.4). There was no effect of BMI on these correlations. 
4.4.5 Fat metabolism gene expression, and effect of BMI on correlation with whole body protein 
kinetics 
FATP1 (p < 0.0001), FATP4 (p < 0.0001), ACC (p < 0.0001), PPARα (p < 0.0001), and 
SREBP1 (p < 0.0001), were upregulated in OW/OB group compared to the NW group (Figure 
4.5). Hierarchical regression analysis showed no significant correlation between all gene 
expressions and PS or PB (Table 4.5). Furthermore, there were negative correlations between 
expression of PPARα (β = -0.189, p = 0.038), SREBP1 (β = -0.199, p = 0.029) and NB (Table 
4.5). There was no effect of BMI on these correlations. 
4.5 Discussion  
This study is the first to demonstrate that gene expression related to autophagy, 
mitochondrial biogenesis, fatty acid transport, adipogenesis, and fatty acid synthesis is 





ATF4 was firstly reported to play a critical role in skeletal muscle atrophy during fasting. 
(8). GADD45A, was upregulated in a skeletal muscle atrophy model induced by denervation, 
which was independent of ATF4 level (3). Here we show expression of ATF4 and GADD45A 
does not change in the OW/OB group, compared with NW group (Figure 4.2), suggesting that 
ATF4-GADD45A axis was not activated in the skeletal muscle of OW/OB group. In addition, it 
was reported that expression of genes involved in autophagy pathway such as ULK1, ATG5, 
ATG7, LC3B, p62, Beclin1 were not different in the skeletal muscle between lean and obese 
adults at fasted state, and there was no difference in the protein contents of ATG7, LC3B-II/I 
ratio, and p62 (26). Inconsistent to this report, we find genes such as ATG3, ATG7, Beclin1, 
LC3B, and p62 were upregulated in the muscle from overweight and obese adults (Figure 4.2). 
Based on the contradictory results between our findings and report from Kruse et al, we suggest 
that a further investigation of autophagy, such as morphology of autophagosome by localizing 
the autophagosome membrane marker p62 and LC3B, in the skeletal muscle of obese adults is 
needed. Overall, we suggested that increased autophagy signal in the overweight and obese 
adults could be partially responsible for muscle atrophy in obesity reported from other studies. 
Two muscle specific E3 ligases, Atrogin1 and MuRF1, are widely reported to be 
involved in muscle atrophy. Atrophic muscle cells were showed to have higher Atrogin1 
expression, while knockdown of Atrogin1 prevented muscle atrophy (27). Another study also 
demonstrated expression of Atrogin1 and MuRF1 were upregulated in muscle atrophy cell model 
(37). Under obesogenic condition such as diet-induced obesity, rats fed with high-fat high-
sucrose diet for 12 weeks showed lower expression of Atrogin1 in the vastus lateralis muscle, 
while MuRF1 was not changed (6). Another in vivo study showed increased ubiquitin signal and 




mice (1). In the present study, we did not find any significant difference in the expression of 
Atrogin1 and MuRF1 between NW and OW/OB groups (Figure 4.3). We consider the 
inconsistency between our results and others is due to the difference in the models, as previous 
studies only examined Atrogin1 and MuRF1 expression in diet-induced obese mice. Based on 
our findings, we suggest UPS might be the factor contributing to the muscle atrophy in obesity. 
Mitochondrial dysfunctions such as decreased complex I activity and mitochondrial area 
in the skeletal muscle from obese adults were firstly reported by Kelly et al (20). More recently, 
in an in vivo model of diet-induced obesity, obese mice showed higher protein content of COX-
IV and cytochrome c than mice fed with normal diet in the skeletal muscle (12). Unchanged 
UCP2 expression and upregulated UCP3 expression were firstly shown in the skeletal muscle of 
obese human (35). However, expression of UCP2 was found upregulated in OW/OB group in the 
present study (Figure 4.5). We suggest the measurement of UCP2 protein content and 
mitochondrial bioenergetics of obese muscle are needed for further investigation. One study 
using grape extract as dietary supplementation for obese Zucker rats showed improved 
mitochondrial respiration of skeletal muscle, accompanied with decreased expression of NRF1 
(32). This study suggests that NRF1 plays a negative role in mitochondrial function in skeletal 
muscle. Our result also showed an increased expression of NRF1 in the OW/OB group. This 
suggests an elevation in mitochondrial biogenesis. However, mitochondrial content and size 
measurements are needed to verify this. 
It was firstly shown PGC1α coactivated PPARα to promote transcription of 
mitochondrial fatty acid oxidation-related genes (34). Here, it was shown that PPARα expression 
was upregulated in the OW/OB adults (Figure 4.5). Activation of fatty acid oxidation in skeletal 




find any difference in the expression of Cpt1, which is considered as a central regulator for fatty 
acid oxidation in skeletal muscle, between NW and OW/OB adults. Over-expressing muscle 
specific Cpt1 in diet-induced obese rats increased fatty acid oxidation in the skeletal muscle (4). 
Therefore, we suggested unchanged Cpt1 level, which could be shown as lowered Cpt1 
enzymatic activity, might cancel the stimulative effect of PPARα upregulation on fatty acid 
oxidation in overweight and obese adults. Previous in vivo study from our lab showed increased 
expression of fatty acid synthase in the skeletal muscle of obese Zucker rats fed with a low 
protein diet (9). This indicated a higher signal of fatty acid synthesis in the skeletal muscle under 
obesogenic conditions. In addition, O’Neill et al reported that increased fatty acid oxidation, 
induced by AICAR administration, a drug activates AMPK, was not effective in ACC knockin 
mice (31). Consistent with this, we found elevated expression of ACC in the skeletal muscle of 
overweight and obese adults. SREBP1 was shown to play an important role in the differentiation 
of adipocyte (10). Moreover, mice fed with high-fat diet had slight, but not significant, increase 
in the expression of SREBP1 in skeletal muscle (7). The insignificance could be explained by 
insufficient sample size as there were only six mice included in the high-fat diet group. In the 
present study, we found significant upregulation of SREBP1 in the skeletal muscle of overweight 
and obese adults. Conclusively, we suggested that upregulation of SREBP1 played a role in 
adipogenesis around skeletal muscle, and upregulated ACC drove higher intramyocellular fatty 
acid accumulation. 
Obese adults had significantly lower whole body and muscle protein synthesis rate versus 
lean counterparts (13). However, this study did not measure whole body and muscle protein 
degradation, in which net balance between protein synthesis and breakdown was unknown. 




between lean and obese adults (11). In present study, we also did not observe any difference in 
net balance between normal weight and overweight and obese adults. Hierarchical regression 
analysis revealed that autophagy, UPS, mitochondrial biogenesis, and fat metabolism-related 
genes were not correlated with whole body protein kinetics (PS, PB, and NB) after introducing 
BMI as moderator. Therefore, we concluded that these gene expressions could not be used as 
predictor for whole body protein kinetics. 
There are few limitations in present study. First, we only measured the expression of 
selected genes from two weight groups, differentiated by BMI. The differences observed at 
transcription level might not be reflected on translational level. Second, we only compared whole 
body protein kinetics between normal weight and overweight and obese adults, which could not 
explain muscle protein kinetics.  
In conclusion, the present study demonstrated that body weight may impact gene 
expression related to autophagy, mitochondrial biogenesis, and fat synthesis in skeletal muscle 
from overweight and obese adults. As the proposed signal scheme shown in Figure 6, we 
suggested that increased autophagy-related gene expression could contribute to increased muscle 
protein breakdown. Although higher expression of mitochondrial biogenesis (NRF1 and UCP2) 
and fatty acid oxidation (PPARα) related genes were observed in overweight and obese adults, 
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Figure 4.1. Comparison of whole body kinetics between NW and OW/OB groups. PS, protein 
synthesis; PB, protein breakdown; NB, net balance; NW, normal weight; OW/OB, overweight 






Figure 4.2. Comparison of gene expression of autophagy related genes between NW and 
OW/OB groups. NW, normal weight; OW & OB, overweight and obese. ATG3, autophagy 
related 3; ATG5, autophagy related 5; ATG7, autophagy related 7; LC3B, microtubule-
associated proteins 1A/1B light chain 3B; ULK1, Unc-51 like autophagy activating kinase 1; 
p62, nucleoporin 62; p53, nucleoporin 53; ATF4, activating transcription factor 4; GADD45A, 
growth arrest and DNA damage inducible alpha. *p < 0.05. Values are expressed as mean ± 






Figure 4.3. Comparison of gene expression of ubiquitin-proteasome system related genes 
between NW and OW/OB groups. NW, normal weight; OW/OB, overweight and obese. 
Atrogin1, muscle-specific F-box protein; MuRF1, muscle RING-finger protein-1. *p < 0.05. 





Figure 4.4. Comparison of gene expression of mitochondrial biogenesis related genes between 
NW and OW/OB groups. NW, normal weight; OW/OB, overweight and obese. NRF1, nuclear 
respiratory factor 1; PGC1α, peroxisome proliferator-activated receptor gamma coactivator 1 
alpha; PPARγ, peroxisome proliferator-activated receptor gamma; Tfam, mitochondrial 
transcription factor a; UCP2, uncoupling protein 2. *p < 0.05. Values are expressed as mean ± 






Figure 4.5. Comparison of gene expression of fat metabolism related genes between NW and 
OW/OB groups. NW, normal weight; OW/OB, overweight and obese. Cpt1b, muscle-specific 
carnitine palmitoyltransferase 1; FATP1, fatty acid transport protein 1; ; FATP4, fatty acid 
transport protein 4; ACC, acetyl-CoA carboxylase; PPARα, peroxisome proliferator-activated 
receptor alpha; SREBP1, sterol regulatory element-binding protein 1. *p < 0.05. Values are 








Figure 4.6. Schematic diagram of dysregulated gene expression related to autophagy, UPS, 
mitochondrial biogenesis, and fat metabolism in the skeletal muscle of obese adults. Upregulated 
expression of p62, ATG3, ATG5, ATG7, Beclin1, and LC3B in obese muscle might contribute 
to increase autophagy signaling, and further increases muscle protein breakdown. Elevated 
GADD45A and ATF4 expression, consistent with their positive role in muscle atrophy, might 
contribute to muscle atrophy in obesity. Although upregulated NRF1 and UCP2 expression 
indicated increased mitochondrial biogenesis, no change in muscle-specific Cpt1b explained 
unchanged fat oxidation. Higher expression of ACC, PPARα, and SREBP1 suggested increased 
fatty acid synthesis, and higher expression of FATP1 and FATP4 suggested increased fatty acid 
transport to facilitate fat accumulation in skeletal muscle of obese adults. Figure drawn using 








Table 4.1. Subjects characteristics.  
 
  NW OW/OB 
Age 43 ± 5.1 47.7 ± 3.4 
Sex (F/M) 10/2 11/20 
BW, kg 62.9 ± 2.2 89.8 ± 2.3* 
BMI, kg/m2 22.6 ± 0.7 29.2 ± 0.6* 
LBM, kg 41.0 ± 1.9 56.3 ± 1.7* 
Fat Mass, kg 21.8 ± 1.2 29.0 ± 1.5* 
 
Participants in OW/OB group have higher BW, BMI, LBM, and fat mass than participants in 
NW group. NW, normal weight; OW/OB, overweight and obese; BW, body weight; BMI, body 
mass index; LBM, lean body mass. *p < 0.05. Values are expressed as mean ± SEM. (NW, n = 




















Table 4.2. Results of hierarchical regression analysis of correlation between autophagy related 
gene expression and whole body protein kinetics.  
 
PS ATF4 GADD45A ATG3 ATG5 ATG7 Beclin1 ULK1 p62 p53 LC3B 
Step 1             
β 0.747 0.747 0.747 0.747 0.744 0.755 0.744 0.747 0.747 0.747 
R2 0.558 0.558 0.558 0.558 0.553 0.570 0.554 0.559 0.558 0.558 
p <0.001* <0.001* <0.001* <0.001* <0.001* <0.001* <0.001* <0.001* <0.001* <0.001* 
Step 2             
β -0.142 -0.154 -0.145 -0.161 -0.130 -0.175 0.080 -0.118 -0.076 -0.131 
R2 0.577 0.581 0.579 0.583 0.569 0.600 0.559 0.572 0.564 0.575 
p 0.200 0.159 0.183 0.142 0.239 0.109 0.500 0.277 0.487 0.230 
Step 3             
β 0.006 0.002 0.222 -0.001 0.002 -0.025 0.025 0.005 0.023 0.000 
R2 0.577 0.581 0.579 0.583 0.570 0.601 0.560 0.572 0.564 0.575 
p 0.959 0.982 0.997 0.996 0.985 0.823 0.825 0.965 0.833 0.997 
Step 4            
β 0.79 0.785 -0.612 -1.18 -0.977 -1.256 0.327 -0.983 -0.868 -1.332 
R2 0.608 0.604 0.611 0.61 0.59 0.633 0.561 0.595 0.587 0.59 
p 0.103 0.156 0.092 0.12 0.193 0.092 0.787 0.189 0.257 0.138 
PB                     
Step 1             
β 0.396 0.396 0.396 0.396 0.391 0.427 0.412 0.396 0.396 0.396 
R2 0.157 0.157 0.157 0.157 0.153 0.182 0.170 0.157 0.157 0.157 
p 0.010* 0.010* 0.010* 0.010* 0.013* 0.007* 0.009* 0.010* 0.010* 0.010* 
Step 2            
β -0.035 -0.066 -0.044 -0.064 -0.034 -0.081 0.079 -0.011 -0.003 -0.031 
R2 0.158 0.161 0.159 0.161 0.154 0.189 0.175 0.157 0.157 0.158 
p 0.818 0.663 0.772 0.675 0.827 0.597 0.624 0.942 0.984 0.841 
Step 3             
β -0.078 -0.083 -0.082 -0.084 -0.082 -0.113 -0.076 -0.076 -0.073 -0.080 
R2 0.164 0.168 0.165 0.168 0.161 0.201 0.181 0.162 0.162 0.164 
p 0.609 0.586 0.594 0.583 0.600 0.471 0.622 0.620 0.633 0.602 
Step 4             
β -1.19 -1.057 -0.938 -1.107 -0.887 -1.113 0.087 -0.851 -0.645 -1.277 
R2 0.199 0.196 0.185 0.196 0.161 0.229 0.181 0.182 0.173 0.189 
p 0.217 0.271 0.35 0.271 0.358 0.27 0.99 0.379 0.505 0.282 
NB                     
Step 1             
β 0.823 0.823 0.823 0.823 0.820 0.824 0.816 0.823 0.823 0.823 
R2 0.677 0.677 0.677 0.677 0.673 0.679 0.666 0.677 0.677 0.677 
p <0.001* <0.001* <0.001* <0.001* <0.0001* <0.001* <0.001* <0.001* <0.001* <0.001* 
Step 2             
β -0.213 -0.191 -0.207 -0.207 -0.194 -0.216 0.035 -0.205 -0.138 -0.200 
R2 0.720 0.712 0.719 0.718 0.710 0.724 0.667 0.718 0.696 0.716 
p 0.021* 0.037* 0.023* 0.024* 0.036* 0.019* 0.732 0.024* 0.137 0.028 
Step 3             
β 0.123 0.124 0.177 0.120 0.122 0.115 0.163 0.119 0.147 0.117 
R2 0.735 0.728 0.732 0.732 0.725 0.737 0.693 0.732 0.717 0.729 
p 0.157 0.160 0.182 0.171 0.176 0.203 0.093 0.176 0.100 0.188 
Step 4             
β -0.536 -0.425 -0.628 -0.607 -0.54 -0.792 0.499 -0.608 -0.69 -0.644 
R2 0.738 0.729 0.737 0.737 0.728 0.747 0.696 0.734 0.739 0.722 




Table 4.3. Results of hierarchical regression analysis of correlation between ubiquitin 
proteasome system related gene expression and whole body protein kinetics.  
 
PS Atrogin1 MuRF1 
Step 1     
β 0.747 0.744 
R2 0.558 0.553 
p <0.001* <0.001* 
Step 2     
β -0.159 -0.148 
R2 0.582 0.573 
p 0.149 0.191 
Step 3     
β 0.027 0.001 
R2 0.583 0.573 
p 0.801 0.996 
Step 4     
β -1.274 -1.131 
R2 0.619 0.601 
p 0.074 0.128 
PB     
Step 1     
β 0.396 0.391 
R2 0.157 0.153 
p 0.010* 0.013* 
Step 2     
β -0.066 -0.034 
R2 0.161 0.154 
p 0.670 0.831 
Step 3     
β -0.071 -0.081 
R2 0.166 0.161 
p 0.639 0.602 
Step 4     
β -1.526 -0.911 
R2 0.228 0.182 
p 0.098 0.344 
NB     
Step 1     
β 0.823 0.820 
R2 0.677 0.673 
p <0.001* <0.001* 
Step 2     
β -0.202 -0.228 
R2 0.716 0.721 
p 0.029* 0.016* 
Step 3     
β 0.153 0.119 
R2 0.739 0.735 
p 0.077 0.179 
Step 4     
β -0.69 -0.644 
R2 0.739 0.722 




Table 4.4. Results of hierarchical regression analysis of correlation between mitochondrial 
biogenesis related gene expression and whole body protein kinetics.  
 
PS NRF1 PGC1α PPARγ Tfam UCP2 
Step 1        
β 0.747 0.747 0.798 0.747 0.747 
R2 0.558 0.558 0.637 0.558 0.558 
p <0.001* <0.001* <0.001* <0.001* <0.001* 
Step 2        
β -0.110 -0.091 -0.128 -0.126 -0.099 
R2 0.570 0.566 0.652 0.574 0.568 
p 0.313 0.408 0.328 0.246 0.366 
Step 3        
β 0.009 0.005 -0.009 0.010 0.014 
R2 0.570 0.566 0.652 0.574 0.568 
p 0.933 0.966 0.946 0.930 0.897 
Step 4        
β -1.107 -0.903 -0.561 -0.854 -1.136 
R2 0.593 0.585 0.66 0.598 0.592 
p 0.165 0.204 0.499 0.149 0.149 
PB           
Step 1        
β 0.396 0.396 0.452 0.396 0.396 
R2 0.157 0.157 0.204 0.157 0.157 
p 0.010* 0.010* 0.021* 0.010* 0.010* 
Step 2        
β -0.018 0.045 -0.053 -0.012 -0.021 
R2 0.157 0.159 0.207 0.157 0.157 
p 0.907 0.767 0.784 0.934 0.889 
Step 3        
β -0.076 -0.066 -0.097 -0.075 -0.075 
R2 0.163 0.163 0.216 0.162 0.163 
p 0.619 0.670 0.623 0.624 0.622 
Step 4        
β -0.879 -0.565 -0.374 -0.826 -0.723 
R2 0.179 0.173 0.219 0.192 0.174 
p 0.4 0.506 0.756 0.259 0.493 
NB           
Step 1 (Age)       
β 0.823 0.823 0.818 0.823 0.823 
R2 0.677 0.677 0.699 0.677 0.677 
p <0.001* <0.001* <0.001* <0.001* <0.001* 
Step 2 (Gene)       
β -0.180 -0.235 -0.158 -0.217 -0.154 
R2 0.790 0.731 0.692 0.724 0.700 
p 0.049* 0.009* 0.201 0.016* 0.096 
Step 3 (BMI)       
β 0.127 0.104 0.123 0.126 0.135 
R2 0.725 0.741 0.707 0.739 0.718 
p 0.154 0.231 0.310 0.146 0.133 
Step 4 (BMI × Gene)       
β -0.799 -0.87 -0.493 -0.403 -1.077 
R2 0.734 0.754 0.712 0.741 0.738 





Table 4.5. Results of hierarchical regression analysis of correlation between fat metabolisms 
related gene expression and whole body protein kinetics.  
 
PS Cpt1 FATP1 FATP4 PPARα SREBP1 ACC 
Step 1 (Age)        
β 0.747 0.747 0.747 0.747 0.747 0.747 
R2 0.558 0.558 0.558 0.558 0.558 0.558 
p <0.001* <0.001* <0.001* <0.001* <0.001* <0.001* 
Step 2 (Gene)        
β -0.028 -0.127 -0.138 -0.131 -0.135 -0.126 
R2 0.559 0.574 0.577 0.575 0.576 0.574 
p 0.808 0.242 0.206 0.226 0.217 0.245 
Step 3 (BMI)        
β 0.022 0.000 0.003 0.002 0.003 0.003 
R2 0.524 0.574 0.577 0.575 0.576 0.574 
p 0.840 0.974 0.977 0.984 0.975 0.976 
Step 4 (BMI × Gene)        
β 1.201 -1.057 -1.08 -0.98 -1.082 -0.972 
R2 0.531 0.593 0.597 0.593 0.595 0.594 
p 0.22 0.2 0.195 0.215 0.181 1.621 
PB             
Step 1 (Age)        
β 0.396 0.396 0.396 0.396 0.396 0.396 
R2 0.157 0.157 0.157 0.157 0.157 0.157 
p 0.010* 0.010* 0.010* 0.010* 0.010* 0.010* 
Step 2 (Gene)   
     
β -0.100 -0.045 -0.066 -0.039 -0.036 -0.049 
R2 0.166 0.159 0.161 0.158 0.158 0.159 
p 0.522 0.766 0.663 0.798 0.814 0.744 
Step 3 (BMI)        
β -0.077 -0.082 -0.084 -0.081 -0.080 -0.083 
R2 0.172 0.165 0.168 0.165 0.164 0.166 
p 0.611 0.595 0.583 0.598 0.603 0.591 
Step 4 (BMI × Gene)        
β 1.568 -0.923 -1.013 -0.803 -0.917 -0.77 
R2 0.206 0.182 0.188 0.179 0.182 0.178 
p 0.224 0.398 0.351 0.437 0.397 0.445 
NB             
Step 1 (Age)        
β 0.823 0.823 0.823 0.823 0.823 0.823 
R2 0.677 0.669 0.677 0.677 0.677 0.677 
p <0.001* <0.001* <0.001* <0.001* <0.001* <0.001* 
Step 2 (Gene)        
β 0.092 -0.173 -0.162 -0.189 -0.199 -0.164 
R2 0.685 0.706 0.703 0.712 0.716 0.704 
p 0.337 0.060 0.079 0.038* 0.029* 0.073 
Step 3 (BMI)        
β 0.152 0.124 0.127 0.121 0.121 0.125 
R2 0.708 0.721 0.718 0.727 0.730 0.719 
p 0.096 0.166 0.158 0.175 0.169 0.165 
Step 4 (BMI × Gene)        
β -0.019 -0.642 -0.555 -0.67 -0.703 -0.697 
R2 0.708 0.727 0.722 0.733 0.737 0.726 







Table 4.6. Sequences of primers used for real-time PCR. 
 
Gene Name Forward Sequence (5’ – 3’) Reverse Sequence (5’ – 3’) 
Autophagy     
P62 GAGCGGCTCTGGACACCAT GTGGGCAAAAGTGGTCACAA 
P53 TGCAATAGGTGTGCGTCAGAA CCCCGGGACAAAGCAAA 
ATF4 CAGACGGTGAACCCAATTGG CAACCTGGTCGGGTTTTGTT 
GADD45A GATGTGGCTCTGCAGATCCA ATGTCGTTCTCGCAGCAAAA 
Beclin1 CAAGATCCTGGACCGTGTCA CCTGGGCTGTGGTAAGTAATGG 
LC3B GGCGCTTACAGCTCAATGCT TGCTGTGTCCGTTCACCAA 
ULK1 AAAGCGAATTTTGTGTGATTTCC CCCAACAATTCCAAAGGTTTATTT 
ATG3 GGGCCGGCCGCTACT CCAGTGCCTTTCCCTTCACA 
ATG5 AAACCCATTCCTTCCAAGCTAGT GCCAGGGACCACAGTGAAA 
ATG7 AGCAGCCCACAGATGGAGTAG ACGGTCACGGAAGCAAACA 
UPS     
Atrogin1 AAGGTAGCGGGTGTGTATTATGC TCATGGGAAAGGGTATGTGAATC 
MuRF1 CAACCTGTGCCGGAAGTGT CTGGTCCAGTAGGGATTTGCA 
Mitochondrial 
Biogenesis 
    
PPARγ GACCACTCCCACTCCTTTGA GATGCAGGCTCCACTTTGAT 
PGC1α GGAACTGCAGGCCTAACTCC CACTGTCCCTCAGTTCACCG 
NRF1 CCACAGGCAGATGAATGTCTTG TCCTGGGAAGGAGAGGAGATG 
Tfam ATGCTTATAGGGCGGAGTGG TGGTTTCCTGTGCCTATCCA 
UCP2 TCAGTGCTGGTGGAGTTGACA GGGATCCTGGCTGGTACGA 
Fat Metabolism     
PPARα GACCACTCCCACTCCTTTGA GATGCAGGCTCCACTTTGAT 
ACC CATTAGCACAGACATACCT CACCAATACTCACTTCACT 
SREBP1 GTATCAGGCAACTCACTAC AACATCCATCACTCAACAG 
FATP1 TCTTCTGGTCACTACTCA CCTCGCTCTGTAATCATAA 
FATP4 CCTGTTGTTCCTCTACTT CCTGATGGTCTTGATGAA 
Cpt1 TGAGCGACTGGTGGGAGGAG GAGCCAGACCTTGAAGTAGCG 








5 Chapter 4. Net Protein Balance is correlated with Increased Expression of Autophagy 
and Fat Metabolism Genes in Skeletal Muscle from Older Adults 
 
5.1 Abstract  
The mechanism of sarcopenia, the main cause for frailty in the older population, is still 
unclear. Autophagy and the ubiquitin-proteasome system are suggested to play a role in 
mediating muscle protein breakdown. In addition, compromised muscle performance has been 
linked with dysfunctional muscular mitochondria. Increased fat deposition and fat infiltration in 
muscle are also frequently seen in older population. Therefore, the first objective of this study 
was to compare the gene expression related to autophagy, the ubiquitin proteasome system, 
mitochondrial biogenesis, and fat metabolism between young and old adults. Our second 
objective was to determine if there was a correlation between whole body protein turnover and 
gene expression in individuals of differing ages. We used real-time quantitative PCR to 
determine the relative fold change of targeted genes in older and young adults. We then 
performed hierarchical regression analysis to determine if age had a moderating effect on the 
correlation between expression of targeted genes and whole body protein turnover. Increase in 
the expression of autophagy related genes, p62, p53, ATG7, and Beclin1, fat metabolism related 
genes, ACC, FATP1, PPARα, SREBP1, mitochondrial biogenesis related gene, and NRF1 were 
observed in older adults. A decrease of the mitochondrial biogenesis related gene, Tfam was 
observed in older adults. In addition, autophagy related genes, ATG3, ATG5, ATG7, Beclin1, 
p62, p53, ubiquitin proteasome system related gen, MuRF1, mitochondrial biogenesis related 
genes, NRF1, PGC1α, Tfam, UCP2, fat metabolism related genes, SREBP1, ACC, PPARα, 
FATP1, were found to be negatively correlated with whole body protein net balance, after age 




autophagy, mitochondrial biogenesis, and fat metabolism could play a role in muscle loss and 
poor physical performance with aging.   
5.2 Introduction 
There are approximately 49 million adults aged 65 and older in the United States, and it 
is estimated that this population will grow to 98 million by 2060 (39). As we age, there is a 
gradual loss of skeletal muscle mass and function (30), called sarcopenia (23, 49), which may be 
caused by a decrease in muscle protein synthesis, an increase in muscle protein breakdown, or a 
combination of those responses (8). For example, myofibrillar protein fractional synthesis rate 
(FSR) and sarcoplasmic protein FSR are reported to be lower in older adults compared to young 
adults (15). There is also a negative correlation between age and whole body amino acid kinetics 
(reflecting protein kinetics) such as phenylalanine and leucine flux with age, which would be 
consistent with accelerated protein breakdown in aging (46). Impairment of muscle protein 
synthesis has been shown to be associated with dysregulation of muscle protein synthesis-related 
signaling in older adults (26). However, no difference in muscle fractional breakdown rate has 
been observed between young and old adults (22), and this has been further supported by 
additional studies demonstrating no difference in muscle protein breakdown rates between 
healthy young and older adults (33, 50). These apparently contradictory findings demonstrate the 
importance of gaining further understanding into the regulation of muscle protein synthesis and 
breakdown in older adults. 
Activation of the autophagic lysosomal system is related to loss of muscle protein in 
catabolic states (41). However, the relation of autophagy to muscle loss with aging has not been 
established (51, 54). Autophagy is usually activated to recycle energy from intracellular damaged 




autophagosome, then fused with the lysosome. Degradation of engulfed proteins and organelles 
recycles usable energy for other pathways, such as protein synthesis, to help cells overcome the 
crisis state (45). When autophagy occurs in mitochondria, it is called mitophagy (53). Increased 
occurrence of mitophagy indicates an increase in dysfunctional mitochondria (34). It has been 
suggested that the accumulation of dysfunctional mitochondria in muscle leads to decreased 
physical performance (17), and upregulated mitophagy decreases availability of functional 
mitochondria (13), indicating that higher level of mitophagy or increased autophagy flux might 
be the potential mechanism in the development of age-related sarcopenia in the skeletal muscle 
of older adults. 
In addition to the possible upregulation of autophagy in sarcopenia, the ubiquitin-
proteasome pathway (UPS) may also be upregulated (14). Two major muscle-specific E3 
ubiquitin ligases, muscle ring finger 1 (MuRF1) and muscle atrophy F-box (MAFbx, also known 
as Atrogin-1), are upregulated at the genetic level in human and rats (14, 17) and at protein level 
in rats under muscle atrophy conditions (2). In addition, two genes were identified to be 
necessary for mediating muscle atrophy, growth arrest DNA damage-inducible 45a (GADD45A) 
(6, 12) and activating transcription factor 4 (ATF4) (18, 21). To date, no study compared the 
expression of Atrogin1, MuRF1, GADD45A, and ATF4 in skeletal muscle of older adults with 
those of young adults.  
Another frequently reported feature of aging skeletal muscle is the imbalance between fat 
mass and muscle mass within skeletal muscle (27). It has been previously reported that intra-
myocellular fat is greater in older adults when compared with their young counterparts (28). It 
has been suggested that accumulated fat mass, whether infiltrated intracellularly or surrounding 




muscle of middle-aged adults compared with young adults (9). It is clear that fat oxidation is 
reduced in skeletal muscle of older adults. However, gene expression related to fat oxidation and 
fat synthesis are still unknown in the skeletal muscle from older adults.  
Therefore, the first objective of this study was to determine differences in gene 
expression related to autophagy, UPS, mitochondria, and fat metabolism in the skeletal muscle 
between older and young adults. Our second objective was to determine whether age has a 
moderating (enhancing or buffering) effect on the correlation between gene expression and 
whole-body protein kinetics: protein synthesis rate (PS), protein breakdown rate (PB), and net 
protein balance (NB). 
5.3 Materials and Methods 
5.3.1 Skeletal muscle biopsies 
This study is a secondary analysis of skeletal muscle (vastus lateralis) samples from two 
previously published studies (35, 36). In total, thirty healthy adults including eleven young (18 – 
40 years) and nineteen older adults (52 – 75 years) were recruited from the Little Rock area 
using local newspaper advertisements and flyers posted around the University of Arkansas for 
Medical Sciences campus and the Little Rock area. Written informed consent was obtained from 
all adults, and the study was approved by the Institutional Review Board at the University of 
Arkansas for Medical Sciences. Exclusion criteria is described in the original published article 
(35). For the current study, we analyzed the baseline muscle samples collected after an overnight 
fast. Characteristics of all participants can be found in Table 5.1. 
5.3.2 Tracer infusion and whole body protein kinetics calculations 
The detailed stable isotope tracer infusion protocol and calculations of protein kinetics 




18-gauge catheters were placed in each lower arm, one for the stable isotope infusion and one for 
blood sample collection. Primed continuous infusions of L-ring-2H5-phenylalanine (prime, 3.07 
μmol/kg; rate, 5.04 μmol·kg-1·h-1) were performed. A priming dose of L-ring-2H4-tyrosine was 
injected (prime, 0.44 μmol/kg) to reach isotopic equilibrium of L-ring-2H4-tyrosine enrichment 
derived from L-ring-2H5-phenylalanine infusion. The muscle biopsy used in the present study 
was taken 2 h after the initiation of the tracer infusion.  
Whole body PS and PB rate were calculated based on the determinations of the rate of 
appearance (Ra) into the plasma of phenylalanine and tyrosine and the fractional Ra of 
endogenous tyrosine converted from phenylalanine (52). Equations used for calculations were 
described in published book chapter (52). 
5.3.3 Quantitative real-time PCR 
RNA samples were isolated using TRIzol (Invitrogen, Waltham, MA), following 
manufacturer instructions. Then cDNA samples were synthesized based on the concentration of 
RNA samples in accordance with manufacturer instruction using Roche Lightcycler 480 system. 
SYBR green master mix (Quanta, Gaithersburg, MD) was used as the reporter dye for 
mitochondrial biogenesis-related genes: peroxisome proliferator-activated nuclear receptor-
gamma (PPARγ), Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-
1α), transcription factor A mitochondrial (Tfam), uncoupling protein 2 (UCP2), and nuclear 
respiratory factor 1 (NRF1); fatty acid metabolism-related genes: carnitine palmitoyltransferase I 
(Cpt1), acetyl-CoA carboxylase (ACC), fatty acid transporter 1 (FATP1), fatty acid transporter 4 
(FATP4), peroxisome proliferator-activated nuclear receptor-alpha (PPARα), sterol regulatory 
element binding transcription factor 1 (SREBP1); autophagy and ubiquitin-proteasome-related 




autophagy related 7 (ATG7), microtubule-associated proteins 1A/1B light chain 3B (LC3B), 
nucleoporin 53 (p53), Unc-51 like autophagy activating kinase 1 (ULK1), Beclin1, growth arrest 
and DNA damage inducible alpha (GADD45A), activating transcription factor 4 (ATF4), 
Atrogin1, and muscle RING-finger protein 1 (MuRF1); . All primer sequences are provided in 
Table 5.6. All primers were ordered from Integrated DNA Technologies (Coralville, IA). All 
samples and controls were analyzed in duplicate. Fold change of target genes of old group versus 
young group were determined using 2-ΔΔCt method (38). 
5.3.4 Statistical analysis 
For RT-PCR results, multiple t-test was used for comparing difference between young 
and old groups. Holm-Sidak method was used for correcting multiple comparisons (1). Statistical 
analyzes were performed and figures were plot in Graphpad Prism, version 6 (San Diego, CA, 
USA). Hierarchical linear regression analysis was performed to test whether age affects the 
association between mRNA and whole-body protein synthesis, protein breakdown, or net-
balance. In step 1, a control variable (AGE or BMI) was entered to examine its influence on the 
dependent variables (PS, PB, and NB). In step 2, independent variables (mRNA) were included 
to examine the influence of the independent variables on the dependent variable while 
controlling with the control variable. In step 3, a moderating variable (AGE) was included to 
examine whether the moderator variable can have a moderating effect on the dependent variable 
in the relationship between the dependent variable and the independent variable. Lastly in step 4, 
all two-way interactions (AGE x mRNA) were introduced to examine whether the moderator 
variable can have a moderating effect on the dependent variable when it interacts with the 
independent variable. In steps 2, 3, and 4, it was considered statistically significant when the 




were provided in supplementary data. Statistical analyzes were performed using IBM SPSS 
statistics, version 23 (Chicago, IL, USA). All significance level was set at 0.05 (α = 0.05). All p 
values that lower than 0.05 were considered as significant.  
 
5.4 Results 
5.4.1 Whole body protein kinetics 
As shown in Figure 5.1, older adults had lower PS than young adults (p < 0.0001). Older 
adults showed a decrease in both PS and PB compared with young adults (p < 0.01). The NB of 
older adults was significantly lower than young adults (p < 0.01).  
5.4.2 Autophagy gene expression, and effect of age on correlation with whole body protein 
kinetics 
Expression of autophagy genes in young versus old muscle are shown in Figure 5.2. 
There was an upregulation in the gene expression of p62 (p < 0.001), ATG7 (p < 0.0001), 
Beclin1 (p < 0.01), and p53 (p < 0.0001) in the older adults, compared with young adults. There 
was no significant moderating effect of age on gene expression in relation to PS or PB (Table 
5.2).  However, the model indicates that age had an effect on the negative correlation between 
NB and the expression of ATG3 (p < 0.05), ATG5 (p < 0.05), Beclin1 (p < 0.01), and p62 (p < 




5.4.3 Ubiquitin-proteasome system gene expression, and effect of age on correlation with whole 
body protein kinetics 
MuRF1 and Atrogin-1 showed no significant difference between older and young adults 
(Figure 5.3). The hierarchical regression analysis indicates that age had an enhancing effect on 
the negative correlation between MuRF1 and NB (Table 5.3) (p < 0.05). 
5.4.4 Differential mitochondrial gene expression, and effect of age on correlation with whole 
body protein kinetics 
NRF1 was higher in the older adults (p < 0.01), whereas Tfam was lower in the older 
adults (p < 0.05), compared with young adults (Figure 5.4). NRF1 (p < 0.01), PGC-1α (p < 0.05), 
Tfam (p < 0.05), and UCP2 (p < 0.05) were negatively correlated with NB, and age had an 
enhancing effect on these correlations (Table 5.4).  
5.4.5 Fatty acid metabolism gene expression in young and older participants, and effect of age 
on correlation with whole body protein kinetics  
FATP1, an insulin-sensitive fatty acid transporter, was upregulated in the older adults 
compared with young adults (p < 0.001) (Figure 5.5). Age had an enhancing effect on the 
correlation between FATP1 and NB (p < 0.05) (Table 5.5). The expression of the adipogenesis 
related gene, PPARα (p < 0.0001) was significantly higher in the older adults compared with 
young adults (Figure 5.5). However, age had no moderating effect on the relationship between 
PPARα and PS or PB (Table 5.5). For NB, there was a negative correlation between PPARα and 
NB. Moreover, there was a moderating effect on the relationship from age (p < 0.05) (Table 5.5). 
The fatty acid biogenesis-related genes, SREBP1 (p < 0.01) and ACC (p < 0.01) were 
upregulated in the older adults (Figure 5.5). Hierarchical regression analysis showed that ACC 




ACC and PS (p < 0.05) (Table 5.5). Both SREBP1 (p < 0.05) and ACC (p < 0.05) were 
negatively correlated with NB. In addition, age had an enhancing effect on both correlations 
(Table 5.5). 
 
5.5 Discussion  
To our knowledge, this is the first studies to demonstrate that expression of genes related 
to autophagy, UPS, mitochondrial biogenesis, and fat metabolism are differentially regulated in 
the skeletal muscle of young and older adults. In addition, this is the first study to our knowledge 
to examine the correlation between age, whole-body protein kinetics, and gene expression related 
to protein synthesis, protein breakdown, and energy metabolism. While the body of research 
examining skeletal muscle gene expression in young versus older rodents is abundant, the 
available data from young and older human skeletal muscle is lacking. This study helps fill this 
research gap. 
In the present study, markers of autophagy such as p62, ATG7, Beclin1, and p53, were 
upregulated in the skeletal muscle of older adults compared with young adults. This is supported 
by studies in skeletal muscle taken from older adults showing upregulated expression of p62 
(42), and aging mice had higher cytosolic expression of p62 and Beclin1 (44). Consistent with 
the mice study (44), we found no differences in LC3B expression in older adults compared with 
young adults. One group of researchers showed that overexpression of GADD45A in the tibialis 
anterior muscle of healthy mice developed significant muscle atrophy (12). However, we found 
no difference in expression of GADD45A and ATF4 between young and older adults. In 
addition, depletion of ATF4, an upstream of GADD45A, reduced the level of muscle atrophy 




artificial skeletal muscle atrophy in model animal and age-related skeletal muscle dysfunction in 
humans. Interpreting our data in the context of the results reported by Sakuma et al (44), we 
suggest that autophagy could be dysregulated, especially upregulation of p62 and Beclin1. Over-
expression of these genes would facilitate the formation of autophagosome in the skeletal muscle 
in aged individuals, which could contribute to muscle loss. At the same time, the gene expression 
patterns of GADD45A and ATF4 under aging scenario need more investigation. Notably, there 
is a discrepancy exists between upregulated autophagy gene expression and decreased PB in 
older adults, compared with young adults. There are other multiple potential reasons for 
decreased PB in older adults: 1) physiologically, autophagy flux is affected by formation of 
autophagosome, infusion of autophagosome and lysosome, and the activity of lysosomal 
enzymes; 2) besides autophagy and UPS contribute to protein breakdown, calpain Ca2+-
dependent cysteine proteases also regulates protein breakdown; 3) the PB we are demonstrating 
here is whole body protein breakdown rate, however, the pattern of muscle protein breakdown 
rate could be different with whole body protein breakdown rate.  
E3 ubiquitin ligase is universally accepted as the central regulator of the UPS process (4). 
Overexpressed E3 ubiquitin ligase would result in over-activation of UPS and unnecessary 
protein degradation (40). Atrogin1 (24) and MuRF1 (10) are two well-established skeletal 
muscle specific E3 ubiquitin ligases, which have been shown to be highly upregulated in mice 
with muscle atrophy (47). Interestingly, there are contrasting  results reported on Atrogin1 and 
MuRF1 expression under muscle atrophy conditions such as suppressed Atrogin-1 expression in 
soleus, medial gastrocnemius, and tibialis anterior muscles of hindlimb unloaded mice (7). In 
addition, Atrogin1 and MuRF1 expressions were upregulated in sedentary men underwent forty-




disuse-related atrophy (43). Another in vivo model of age-related muscle loss showed 
downregulated expression of Atrogin1 and MuRF1 in the gastrocnemius muscle (20). In this 
study, we did not find differences in expressions of either Atrogin-1 or MuRF1 between young 
and older adults. Differences in inducing skeletal muscle loss in the animal models (such as 
dietary restriction-induced atrophy vs. age-related atrophy) could explain the contradictory 
results in the expression patterns of Atrogin1 and MuRF1. Refer to our result, although no 
difference in neither Atrogin1 nor MuRF1 expression was found, the enzymatic activity would 
be different between two age groups.  
Mitochondrial dysfunction has been widely reported in the skeletal muscle of older 
population. It was shown that pre-frail older adults had lower rate of ATP production, lower 
abundance of mitochondrial respiratory complex I, IV, and V and lower enzymatic activity of 
complex I, II and IV than healthy active older adults (3). Similarly, reduced cytochrome c 
oxidase (COX) activity and decreased expression of muscle specific PGC1α and COX I were 
found in the low-functioning older adults (32). In the present study, we found that expression of 
PGC1α and PPARγ, two important transcription factors mediating mitochondrial biogenesis, did 
not differ between young and older adults. NRF1 deficiency was shown to exacerbate 
mitochondrial biogenesis impairment in aging animals (29). Inconsistent with this result, a higher 
NRF1 expression was observed in the older adults in the present study. These findings suggest 
that possible impairments in translational machinery in the skeletal muscle of older adults might 
not be able to translate upregulated NRF1 mRNA into functional protein. The other finding in 
the Figure 3, decreased Tfam expression would account for the discrepancy of increased NRF1 
expression in older adults, since muscle fiber, under age-related muscle loss condition, might 




NRF2, which often functions together with NRF1 to facilitate key mitochondrial metabolic gene 
regulation, is needed.   
Increased fat deposition in aged skeletal muscle has been frequently reported (48). It was 
previously shown that ACC, the rate-limiting enzyme for fatty acid synthesis, was upregulated in 
the skeletal muscle of older adults, which was in line with our finding. In addition, PPARα is 
well known for mediating the activation of adipocyte differentiation for adipogenesis (25). Here, 
we also found upregulated level of PPARα gene in the skeletal muscle from older adults. 
Therefore, we suggest that elevated fat deposition could be the results of enhanced fatty acid 
synthesis and adipogenesis activation caused by ACC and PPARα upregulation. FATP1 and 
FATP4, two skeletal muscle abundant fatty acid transport proteins, were reported to be 
differentially expressed in the muscle of exercised healthy young adults (31). In another in vivo 
model of muscle hypertrophy, myostatin knocked out mice, density of muscle FATP1 and 
FATP4 proteins were lower than wild type (5). These studies suggest FATP1 and FATP4 are 
upregulated with muscle growth. However, we found completely opposite results that FATP1 
and FATP4 upregulated in the skeletal muscle of older adults. But notably, despite the fact that 
upregulated FATP1 and FATP4 level would suggest higher fatty acid transport capacity for 
oxidation, unchanged gene expression of Cpt1, the rate-limiting enzyme for fatty acid oxidation, 
between young and old adults in our study would explain the deficiency in fatty acid catabolism 
reported elsewhere. As a transcription factor that regulates fatty acid synthesis in lipogenic 
tissues, overexpression of SREBP1 was also shown to induce muscle atrophy and decreases 
protein synthesis rate in an in vitro model of human skeletal muscle (16). Consistent with this, 
we found upregulated SREBP1 level in the skeletal muscle of older adults. Therefore, we suggest 




accumulation of fat observed in the skeletal muscle, not fatty acid oxidation, although expression 
of fatty acid transport genes was elevated. 
It is well established that older adults have a lower ratio of whole body protein synthesis 
rate to whole body protein breakdown rate, i.e., negative net protein balance (46). We also 
verified this in the present study. Although we did not find any correlation between autophagy 
gene expression and PS or PB, or any moderating (enhancing or buffering) effect of age on this 
correlation, we did observe negative correlations between NB and gene expressions such as 
ATG3, ATG5, ATG7, Beclin1, p53, and p62 when age was introduced as moderating variable. 
This indicates that when age interacted with these gene expressions, the negative correlations 
were enhanced from non-significant to significant. In addition, after age was introduced, the 
negative correlation between MuRF1 expression and NB became significant. This indicates that 
age had an enhancing effect on the association between MuRF1 and NB. Furthermore, the 
negative correlation between NB and mitochondrial biogenesis-related genes such as NRF1, 
PGC1α, Tfam, and UCP2 became significant after age was introduced, which suggested that age, 
as a moderator, enhanced the negative correlations. Finally, there were negative correlations 
between NB and fatty acid metabolism-related genes such as FATP1 (fatty acid oxidation), 
PPARα (adipogenesis), and ACC, SREBP1 (fatty acid synthesis) after age was introduced. As a 
conclusion, we suggest that whole body protein kinetics in older adults tend to shift to higher 
protein breakdown and lower protein synthesis, and this should account for the muscle loss. 
Multiple mechanisms should be responsible for this shift. Our data showed that older adults had 
higher autophagy, adipogenesis and fatty acid synthesis gene expression than young adults. 




acid synthesis gene expression could function as good negative predictor for whole body protein 
net balance.  
There are several limitations to this study. First, we only measured the gene expression of 
selected genes of two age groups. Any difference found on the transcription level might not be 
reflected on the protein level or protein functional level. Second, we only compared the 
differences in whole body protein kinetics between young and older adults. Volpi et al reported 
the muscle protein fractional synthesis rate was not different between young and old adults (50). 
However, they did not measure muscle protein breakdown rate, which could be a technical 
challenge in measuring protein breakdown rate over a decade ago. Third, we only determined the 
correlations between whole body protein kinetics and expression of genes related to selected 
pathways, and the correlations did not completely reflect the causality.  
In conclusion, the proposed schematic diagram is present in Figure 6. In addition, this is 
the first study to examine the correlation between gene expression related to protein breakdown, 
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Figure 5.1. Whole body protein kinetics in skeletal muscle from young and old participants. 
Older participants had lower PS and PB than young participants. Within older participants, PS 
was lower than PB. Older participants had lower NB than younger participants. PS, protein 
synthesis rate; PB, protein breakdown rate; NB, net balance; LBM, lean body mass. Values 







Figure 5.2. Expression of autophagy genes in skeletal muscle from young and old participants. 
Vastus lateralis muscle biopsies were taken from young and old participants after an overnight 
fasting. Expression of p62, ATG7, Beclin1, and p53 were found higher in the skeletal muscle of 
older participants, compared with younger participants. P62, nucleoporin 62; ATG3, autophagy 
related 3; ATG5, autophagy related 5; ATG7, autophagy related 7; LC3B, microtubule-
associated proteins 1A/1B light chain 3B; p53, nucleoporin 53; ULK1, Unc-51 like autophagy 
activating kinase 1; GADD45A, growth arrest and DNA damage inducible alpha; ATF4, 
activating transcription factor 4. Values represent mean ± SE (young: n = 11, old: n = 19; *, p < 






Figure 5.3. Expression of UPS genes in skeletal muscle from young and old participants. Vastus 
lateralis muscle biopsies were taken from young and old participants after an overnight fasting. 
No difference was found in expression of Atrogin1 and MuRF1 in skeletal muscle of young and 
old adults. Atrogin1, muscle atrophy F-box; MuRF1, muscle RING-finger protein 1. Values 






Figure 5.4. Expression of mitochondrial biogenesis genes in skeletal muscle from young and old 
adults. Vastus lateralis muscle biopsies were taken from young and old participants after an 
overnight fasting. An increase in the expression of NRF1 and a decrease in the expression of 
Tfam were found in the skeletal muscle of old adults. PPARγ, peroxisome proliferator-activated 
nuclear receptor-gamma; PGC-1α, peroxisome proliferator-activated receptor gamma coactivator 
1-alpha; Tfam, transcription factor A mitochondrial; UCP2, uncoupling protein 2; NRF1, nuclear 
respiratory factor 1. Values represent mean ± SE (young: n = 11, old: n = 19; *, p < 0.05; Student 






Figure 5.5. Expression of fat metabolism genes in skeletal muscle from young and old 
participants. Vastus lateralis muscle biopsies were taken from young and old participants after an 
overnight fasting. Upregulation in expression of ACC, FATP1, PPARα, and SREBP1 were 
found in the skeletal muscle of old adults. Cpt1, carnitine palmitoyltransferase I; ACC, acetyl-
CoA carboxylase; FATP1, fatty acid transporter 1; FATP4, fatty acid transporter 4; PPARα, 
peroxisome proliferator-activated nuclear receptor-alpha; SREBP1, sterol regulatory element 
binding transcription factor 1. Values represent mean ± SE (young: n = 11, old: n = 19; *, p < 






Figure 5.6. Schematic diagram showing dysregulated pathways in the skeletal muscle from older 
participants  Upregulated expression of p62, ATG7, Beclin1, and p53 might contribute to 
increased autophagy to further increased protein breakdown and mitophagy. Therefore, net 
balance decreased in the skeletal muscle of older adults. Decreased number of mitochondria 
might cause by decreased expression of Tfam and increased mitophagy in older adults. Increased 
fat deposition in the skeletal muscle of older adults could be explained by upregulation of fatty 
acid synthesis-related genes such as ACC, PPARα, and SREBP1, while expression of fatty acid 








Table 5.1. Participant characteristics.  
  Young Old 
Age 31.0 ±1.5 65.5 ± 1.4 
Female/Male 7/4 9/10 
Body Weight, kg 82.7±1.6 81 ± 3.4 
BMI, kg/m2 26.0 ± 3.5 28.0 ± 0.7 
LBM, % 67.1 ± 1.6 61.4 ± 1.8* 
Fat Mass, % 27.7 ± 1.7 34.6 ± 1.5* 
Values are expressed as mean ± SE. BMI, body mass index; LBM, lean body mass. Older 
























Table 5.2. Hierarchical regression analysis of correlation between autophagy gene expression 
and whole body protein kinetics.  
 
PS ATF4 GADD45A ATG3 ATG5 ATG7 Beclin1 ULK1 p62 p53 LC3B 
Step 1            
β 0.048 0.048 0.048 0.048 0.038 0.034 0.046 0.048 0.048 0.048 
R2 0.002 0.002 0.002 0.002 0.001 0.001 0.002 0.002 0.002 0.002 
p 0.764 0.764 0.764 0.764 0.816 0.836 0.719 0.764 0.764 0.764 
Step 2             
β 0.047 0.003 0.007 0.010 0.013 0.060 0.317 0.004 0.049 0.008 
R2 0.004 0.002 0.002 0.002 0.002 0.005 0.102 0.002 0.005 0.002 
p 0.775 0.987 0.968 0.951 0.940 0.724 0.053 0.981 0.765 0.964 
Step 3            
β 0.780 0.777 0.774 0.781 0.763 0.781 0.717 0.765 0.759 0.769 
R2 0.577 0.581 0.579 0.783 0.570 0.601 0.560 0.572 0.564 0.575 
p <0.001* <0.001* <0.001* <0.001* <0.001* <0.001* <0.001* <0.001* <0.001* <0.001* 
Step 4             
β -0.558 -0.612 -0.652 -0.639 0.292 -0.592 -0.682 -0.67 -0.597 -0.616 
R2 0.604 0.611 0.623 0.633 0.562 0.605 0.598 0.615 0.61 0.609 
p 0.129 0.092 0.057 0.09 0.728 0.092 0.091 0.05 0.113 0.082 
PB                     
Step 1             
β -0.059 -0.059 -0.059 -0.059 -0.066 -0.079 -0.067 -0.059 -0.059 -0.059 
R2 0.004 0.004 0.004 0.004 0.004 0.006 0.004 0.004 0.004 0.004 
p 0.713 0.713 0.713 0.713 0.687 0.634 0.686 0.713 0.713 0.713 
Step 2             
β 0.053 0.005 0.022 0.013 0.016 -0.037 0.200 0.041 0.062 0.028 
R2 0.006 0.004 0.004 0.004 0.005 0.008 0.040 0.005 0.007 0.004 
p 0.748 0.976 0.892 0.935 0.923 0.828 0.228 0.805 0.702 0.885 
Step 3            
β 0.409 0.414 0.409 0.415 0.400 0.445 0.392 0.402 0.339 0.406 
R2 0.164 0.168 0.165 0.168 0.161 0.201 0.181 0.162 0.162 0.164 
p 0.012* 0.010* 0.011* 0.010* 0.014* 0.006* 0.021* 0.012* 0.013* 0.012* 
Step 4             
β -0.311 -0.353 -0.319 -0.315 0.301 -0.306 -0.267 -0.413 -0.375 -0.333 
R2 0.175 0.178 0.177 0.208 0.183 0.174 0.169 0.182 0.181 0.176 
p 0.498 0.457 0.533 0.593 0.78 0.48 0.59 0.35 0.457 0.47 
NB                     
Step 1             
β 0.175 0.175 0.175 0.175 0.166 0.178 0.189 0.175 0.175 0.175 
R2 0.031 0.031 0.031 0.031 0.028 0.032 0.036 0.031 0.031 0.031 
p 0.273 0.273 0.273 0.273 0.305 0.278 0.249 0.273 0.273 0.273 
Step 2             
β 0.012 -0.002 -0.020 -0.001 -0.047 -0.061 0.311 -0.051 0.001 -0.026 
R2 0.031 0.031 0.031 0.031 0.030 0.035 0.132 0.033 0.031 0.031 
p 0.943 0.990 0.903 0.997 0.776 0.716 0.053 0.752 0.994 0.871 
Step 3             
β 0.865 0.852 0.854 0.858 0.844 0.848 0.793 0.847 0.841 0.849 
R2 0.735 0.728 0.732 0.732 0.725 0.737 0.693 0.732 0.717 0.729 
p <0.001* <0.001* <0.001* <0.001* <0.001* <0.001* <0.001* <0.001* <0.001* <0.001* 
Step 4             
β -0.592 -0.634 -0.625 -0.765 0.11 -0.664 -0.849 -0.652 -0.573 -0.669 
R2 0.759 0.762 0.762 0.788 0.693 0.739 0.767 0.76 0.751 0.765 






Table 5.3. Hierarchical regression analysis of correlation between UPS gene expression and 
whole body protein kinetics.  
 
PS Atrogin1 MuRF1 
Step 1     
β 0.048 0.038 
R2 0.002 0.001 
p 0.764 0.816 
Step 2     
β 0.021 0.065 
R2 0.003 0.006 
p 0.896 0.699 
Step 3     
β 0.783 0.783 
R2 0.583 0.573 
p <0.001* <0.001* 
Step 4     
β -0.449 -0.543 
R2 0.597 0.6 
p 0.26 0.138 
PB     
Step 1     
β -0.059 -0.066 
R2 0.004 0.004 
p 0.713 0.687 
Step 2     
β 0.032 0.065 
R2 0.005 0.008 
p 0.846 0.697 
Step 3     
β 0.413 0.405 
R2 0.166 0.161 
p 0.011* 0.015* 
Step 4     
β -0.286 -0.246 
R2 0.174 0.168 
p 0.543 0.596 
NB     
Step 1     
β 0.175 0.166 
R2 0.031 0.028 
p 0.273 0.305 
Step 2     
β -0.006 0.027 
R2 0.031 0.028 
p 0.971 0.871 
Step 3     
β 0.866 0.873 
R2 0.739 0.735 
p <0.001* <0.001* 
Step 4     
β -0.425 -0.657 
R2 0.72 0.769 




Table 5.4. Hierarchical regression analysis of correlation between mitochondrial biogenesis gene 
expression and whole body protein kinetics.  
 
PS NRF1 PGC1α PPARγ Tfam UCP2 
Step 1        
β 0.048 0.048 -0.013 0.048 0.048 
R2 0.002 0.002 0.000 0.002 0.002 
p 0.764 0.764 0.950 0.764 0.764 
Step 2        
β 0.027 0.060 -0.347 -0.018 0.046 
R2 0.003 0.006 0.116 0.003 0.004 
p 0.868 0.720 0.096 0.911 0.779 
Step 3        
β 0.765 0.763 0.763 0.764 0.765 
R2 0.570 0.566 0.652 0.574 0.568 
p <0.001* <0.001* <0.001* <0.001* <0.001* 
Step 4        
β -0.62 -0.398 -0.277 -0.62 -0.72 
R2 0.603 0.58 0.655 0.606 0.609 
p 0.091 0.279 0.676 0.094 0.06 
PB           
Step 1       
β -0.059 -0.059 -0.098 -0.059 -0.059 
R2 0.004 0.004 0.010 0.004 0.004 
p 0.713 0.713 0.632 0.713 0.713 
Step 2        
β 0.044 0.108 -0.197 0.035 0.047 
R2 0.005 0.015 0.047 0.005 0.006 
p 0.789 0.515 0.353 0.830 0.772 
Step 3       
β 0.403 0.392 0.428 0.401 0.404 
R2 0.163 0.163 0.216 0.162 0.163 
p 0.012* 0.015* 0.041* 0.012* 0.012* 
Step 4        
β -0.27 -0.015 0.123 -0.31 -0.37 
R2 0.17 0.163 0.221 0.173 0.175 
p 0.581 0.907 0.708 0.493 0.477 
NB           
Step 1        
β 0.175 0.175 0.118 0.175 0.175 
R2 0.031 0.031 0.014 0.031 0.031 
p 0.273 0.273 0.566 0.273 0.273 
Step 2        
β -0.013 -0.045 -0.355 -0.085 0.017 
R2 0.031 0.033 0.135 0.038 0.031 
p 0.938 0.786 0.085 0.599 0.915 
Step 3        
β 0.847 0.858 0.788 0.846 0.844 
R2 0.725 0.741 0.707 0.739 0.718 
p <0.001* <0.001* <0.001* <0.001* <0.001* 
Step 4        
β -0.78 -0.72 -0.687 -0.71 -0.82 
R2 0.772 0.779 0.749 0.773 0.767 





Table 5.5. Hierarchical regression analysis of correlation between fat metabolism gene 
expression and whole body protein kinetics.  
 
PS Cpt1 FATP1 FATP4 PPARα SREBP1 ACC 
Step 1         
β 0.048 0.048 0.048 0.048 0.048 0.048 
R2 0.002 0.002 0.002 0.002 0.002 0.002 
p 0.764 0.764 0.764 0.764 0.764 0.764 
Step 2         
β -0.232 0.002 -0.009 -0.021 0.000 -0.011 
R2 0.056 0.002 0.002 0.003 0.002 0.002 
p 0.149 0.990 0.956 0.897 1.000 0.945 
Step 3         
β 0.739 0.767 0.769 0.765 0.769 0.765 
R2 0.559 0.574 0.577 0.575 0.576 0.574 
p <0.001* <0.001* <0.001* <0.001* <0.001* <0.001* 
Step 4         
β 0.268 -0.684 -0.655 -0.622 -0.661 -0.71 
R2 0.569 0.617 0.616 0.568 0.617 0.621 
p 0.373 0.051 0.064 0.075 0.056 0.041* 
PB             
Step 1      
   
β -0.059 -0.059 -0.059 -0.059 -0.059 -0.059 
R2 0.004 0.004 0.004 0.004 0.004 0.004 
p 0.713 0.713 0.713 0.713 0.713 0.713 
Step 2         
β -0.206 0.010 -0.010 0.006 0.023 -0.002 
R2 0.046 0.004 0.004 0.004 0.004 0.004 
p 0.202 0.950 0.951 0.971 0.889 0.991 
Step 3         
β 0.370 0.408 0.411 0.406 0.406 0.407 
R2 0.172 0.165 0.168 0.165 0.164 0.166 
p 0.023* 0.011* 0.010* 0.011* 0.011* 0.011* 
Step 4         
β 0.427 -0.453 -0.465 -0.382 -0.401 -0.49 
R2 0.203 0.167 0.19 0.181 0.183 0.191 
p 0.241 0.332 0.332 0.403 0.372 0.296 
NB             
Step 1      
   
β 0.175 0.175 0.175 0.175 0.175 0.175 
R2 0.031 0.031 0.031 0.031 0.031 0.031 
p 0.273 0.273 0.273 0.273 0.273 0.273 
Step 2         
β -0.136 -0.011 -0.002 -0.049 -0.033 -0.018 
R2 0.049 0.031 0.031 0.033 0.032 0.031 
p 0.394 0.945 0.989 0.766 0.838 0.91 
Step 3         
β 0.846 0.843 0.841 0.842 0.849 0.839 
R2 0.708 0.721 0.718 0.727 0.730 0.719 
p <0.001* <0.001* <0.001* <0.001* <0.001* <0.001* 
Step 4         
β -0.11 -0.623 -0.551 -0.61 -0.655 -0.62 
R2 0.713 0.752 0.743 0.756 0.764 0.75 





Table 5.6. Sequences of primers used for real-time PCR. 
 
Gene Name Forward Sequence (5’ – 3’) Reverse Sequence (5’ – 3’) 
Autophagy     
P62 GAGCGGCTCTGGACACCAT GTGGGCAAAAGTGGTCACAA 
P53 TGCAATAGGTGTGCGTCAGAA CCCCGGGACAAAGCAAA 
ATF4 CAGACGGTGAACCCAATTGG CAACCTGGTCGGGTTTTGTT 
GADD45A GATGTGGCTCTGCAGATCCA ATGTCGTTCTCGCAGCAAAA 
Beclin1 CAAGATCCTGGACCGTGTCA CCTGGGCTGTGGTAAGTAATGG 
LC3B GGCGCTTACAGCTCAATGCT TGCTGTGTCCGTTCACCAA 
ULK1 AAAGCGAATTTTGTGTGATTTCC CCCAACAATTCCAAAGGTTTATTT 
ATG3 GGGCCGGCCGCTACT CCAGTGCCTTTCCCTTCACA 
ATG5 AAACCCATTCCTTCCAAGCTAGT GCCAGGGACCACAGTGAAA 
ATG7 AGCAGCCCACAGATGGAGTAG ACGGTCACGGAAGCAAACA 
UPS     
Atrogin1 AAGGTAGCGGGTGTGTATTATGC TCATGGGAAAGGGTATGTGAATC 
MuRF1 CAACCTGTGCCGGAAGTGT CTGGTCCAGTAGGGATTTGCA 
Mitochondrial 
Biogenesis 
    
PPARγ GACCACTCCCACTCCTTTGA GATGCAGGCTCCACTTTGAT 
PGC1α GGAACTGCAGGCCTAACTCC CACTGTCCCTCAGTTCACCG 
NRF1 CCACAGGCAGATGAATGTCTTG TCCTGGGAAGGAGAGGAGATG 
Tfam ATGCTTATAGGGCGGAGTGG TGGTTTCCTGTGCCTATCCA 
UCP2 TCAGTGCTGGTGGAGTTGACA GGGATCCTGGCTGGTACGA 
Fat Metabolism     
PPARα GACCACTCCCACTCCTTTGA GATGCAGGCTCCACTTTGAT 
ACC CATTAGCACAGACATACCT CACCAATACTCACTTCACT 
SREBP1 GTATCAGGCAACTCACTAC AACATCCATCACTCAACAG 
FATP1 TCTTCTGGTCACTACTCA CCTCGCTCTGTAATCATAA 
FATP4 CCTGTTGTTCCTCTACTT CCTGATGGTCTTGATGAA 
Cpt1 TGAGCGACTGGTGGGAGGAG GAGCCAGACCTTGAAGTAGCG 







6 Chapter 5. Leucine decreases intramyocellular lipid deposition in an mTORC1-
independent manner in palmitate-treated C2C12 myotubes 
 
6.1 Abstract 
Higher intramyocellular lipid (IMCL) deposition in skeletal muscle is commonly observed in 
patients with obesity, resulting in mitochondrial damage. Palmitic acid, a saturated fatty acid, has 
been reported to induce obesogenic conditions in C2C12 myotubes. Leucine has been shown to 
improve obesity-related metabolic signatures; however, evidence for the effect of leucine on 
IMCL and the underlying mechanisms are still lacking. The objective of this study was to 
determine the effect of leucine on IMCL deposition and identify the potential mechanisms. 
Palmitate-treated C2C12 myotubes were used as an in vitro model of obesity. Two doses of 
leucine were used: 0.5 mM (postprandial physiological plasma concentration) and 1.5 mM 
(supraphysiological plasma concentration). Rapamycin was used to determine the role of 
mammalian target of rapamycin complex 1 (mTORC1) in leucine’s regulation of lipid deposition 
in C2C12 myotubes. One-way ANOVA followed by Tukey’s post hoc test was used to calculate 
differences between treatment groups. Our results demonstrate that leucine reduces IMCL 
deposition in an mTORC1-independent fashion. Furthermore, leucine acts independently of 
mTORC1 to upregulate gene expression related to fatty acid metabolism and works through both 
mTORC1-dependent and mTORC1-independent pathways to regulate mitochondrial biogenesis 
in palmitate-treated C2C12 myotubes. In agreement with increased mitochondrial biogenesis, 
increased mitochondrial content, circularity, and decreased autophagy are observed in the 
presence of 1.5 mM leucine. Taken together, the results indicate leucine reduces IMCL 





Obesity continues to be a growing concern in the United States and around the world 
(17). According to the Centers for Disease Control and Prevention, 39.8% of adults and 18.5% of 
children are classified as obese (35a). Obesity is frequently accompanied by multiple chronic 
diseases, such as type 2 diabetes, cardiovascular diseases, and certain types of cancer. One of the 
most significant features of obesity is the overaccumulation of fat mass (6). Overaccumulation of 
fat mass with obesity increases the physical load placed on skeletal muscle, increasing the 
susceptibility of skeletal muscle to intramyocellular lipid (IMCL) deposition, which can result in 
physical damage, leading to decreased quality of life (45). 
Skeletal muscle is a major site of metabolic activity and the most abundant tissue in the 
human body (39). For skeletal muscle to function at optimal levels, the efficient activation of 
processes that regulate muscle development, growth, regeneration, and metabolism is required 
(15). A loss or reduction in skeletal muscle function often leads to increased morbidity and 
mortality, either directly or indirectly, via the development of secondary diseases, such as 
diabetes, obesity, and cardiovascular disease. Mitochondria are particularly important for skeletal 
muscle function. The mitochondria play a critical role in fuel utilization and energy production 
and impact whole-body metabolic homeostasis (37). Mitochondrial dysfunction is frequently 
associated with ectopic lipid deposition, which may result in reduced insulin signaling and action 
and increased risk for development of obesity and other chronic diseases. Thus, improvement of 
mitochondrial function may decrease the amount of intracellular lipids and allow for a more 
adaptive response to chronic fuel excess, as with obesity or inactivity (37, 44). 
Mitochondrial biogenesis refers to the generation of more mitochondria in response to 




biogenesis is influenced by environmental stress, such as exercise, caloric restriction, and 
oxidative stress (20). Peroxisome proliferator- activated receptor-α-coactivator-1α (PGC1α), 
PGC1α, nuclear respiratory factors (NRFs) -1 and -2, and mitochondrial transcription factor A 
(Tfam) are major regulators of mitochondrial biogenesis. AMP-activated protein kinase regulates 
intracellular energy metabolism in response to acute energy crises and is a major regulator of 
mitochondrial biogenesis through PGC1α and the NRFs (20). 
Mitochondria also play a key role in ensuring adequate levels of ATP needed for muscle 
contraction (37). In addition, the capacity of skeletal muscle to contribute to whole-body energy 
expenditure is related to the fact that muscle makes up ~40% of total body mass and accounts for 
20%–30% of total resting oxygen uptake (47). This indicates that mitochondrial functional 
capacity is likely to directly affect muscle metabolic function and have a significant impact on 
whole-body metabolism (37). 
At the molecular and structural level, mitochondrial biogenesis and function are reduced 
in patients with obesity (38). For example, when patients with obesity were compared with their 
lean counterparts, a lower mitochondrial content was observed in skeletal muscle (21). A 
comparative proteomic analysis examined subsarcolemmal and intermyofibrillar mitochondrial 
proteins from patients with obesity, and lean patients which found an increase in proteins related 
to electron transport chain complex II and citric acid cycle with obesity (24). Increased 
intramyocellular lipid content is associated with reduced mitochondrial phosphorylation activity 
in skeletal muscle (32). In skeletal muscle taken from women with obesity, the expression of 
carnitine palmitoyltransferase (Cpt) 1b, the rate-limiting enzyme responsible for fatty acid 




receptor γ (PPARγ), PGC1α, and NRF1, suggesting these genes may play a role in the 
dysregulation of muscle function associated with obesity (36). 
The mammalian target of rapamycin complex 1 (mTORC1) is a kinase that regulates cell 
size, growth, and survival and is an important component of nutrient and energy pathways. 
Specifically, mitochondrial oxidative function is controlled by mTORC1 through a ying yang 1-
PGC1 transcriptional complex (8). Ying yang 1 is a transcription factor and is a common target 
of both mTORC1 and PGC1α. In addition, humans and rodents treated with rapamycin (an 
mTORC1 inhibitor) display symptoms of diabetes, such as elevated blood triglycerides and 
cholesterol and reduced oxidative function in skeletal muscle (8). This suggests that an increase 
in mTORC1 signaling could result in improved mitochondrial oxidative function. 
A crucial function of mTORC1 is the coupling of cellular nutrient sensing to metabolic 
homeostasis. The branched-chain amino acid leucine is an essential amino acid that serves as a 
potent activator of the mTORC1 signaling pathway, leading to activation of protein synthesis (2). 
Leucine has also been shown to improve adipocyte lipid metabolism, increase mitochondrial 
ATP production rate (46), and improve mitochondrial biogenesis in skeletal muscle (43). In 
addition, increasing dietary leucine has been shown to decrease diet-induced obesity, 
hypercholesterolemia, and hyperglycemia in mice fed a high-fat diet (29, 51). More recently, it 
has been shown that increasing leucine concentrations in C2C12 myotubes can decrease fat 
uptake into cells through an increase in fat oxidation (11), increase expression of genes related to 
mitochondrial biogenesis (41), and increase mitochondrial density (48). Taken together, these 





Therefore, the objective of this study was to determine the effect of leucine 
supplementation on IMCL deposition under obese conditions and identify potential mechanisms 
of action using an in vitro model. We hypothesized that leucine would decrease IMCL in C2C12 
myotubes through activation of the mTORC1 pathway, potentially through increased 
mitochondrial function. 
6.3 Materials and Methods 
6.3.1 Cell culture and experimental design 
C2C12 mouse myoblasts were obtained from American Type Culture Collection 
(Rockville, MD) and grown in Dulbecco’s modified Eagle’s medium (DMEM; Thermo Fisher 
Scientific, Waltham, MA) containing 25 mmol/L glucose, 10% FBS (Gibco, Berlin, Germany), 
and antibiotics (1% penicillin-streptomycin) at 37°C in 5% CO2. When the number of cells 
reached 70%–80% confluence, cells (passage < 12) were seeded into 6-well plates for 
experimentation. Differentiation of C2C12 cells was induced using DMEM containing 2% horse 
serum and 1% antibiotics. Every well was seeded with 100,000 cells. Cells were then incubated 
in the differentiation media for 4 days, and media was changed every 24 h. For all treatments, 
cells were seeded in triplicate and then each experiment was repeated three times, yielding nine 
wells per treatment. All differentiated cells were divided into two groups: palmitate (PA) treated 
and control. Furthermore, each group was assigned the following treatments: control (no 
treatment), rapamycin, 0.5 mM leucine, 1.5 mM leucine, 0.5 mM leucine + rapamycin, and 1.5 
mM leucine + rapamycin. 
6.3.2 Preparation of palmitic acid-BSA solution 
Palmitic acid was conjugated with fatty acid-free BSA according to Chavez et al. (5). 




90°C and conjugated with 2% fatty acid-free BSA, which was prepared in a customized 
Dulbecco’s modified Eagle’s medium that contains no L-leucine (leucine-free DMEM; Athena 
Enzyme System, Baltimore, MD) and incubated in an isothermal water bath at 37°C. This was 
the stock solution of palmitic acid (PA) at a concentration of 4 mM. Stock palmitic acid solution 
was diluted with leucine-free DMEM to 0.75 mM for a final working solution (26). The dose of 
palmitate (PA) used in this study was adapted from a previously published study by Li et al. (26). 
In addition, recent research demonstrates that cell death starts to manifest in C2C12 myotubes 
treated with PA over 24 h (4). To determine optimal treatment time with PA, we conducted a 
pilot study using 6, 12, and 24-h incubations with PA. Oil red O stain showed that C2C12 
myotubes treated with PA for 24 h had the highest percentage of intracellular lipid droplet 
deposition with no change in cell death compared with the 6 and 12-h time points (Figure 5.7). 
Therefore, 24 h PA treatment was selected for later experiments to induce maximum intracellular 
fatty acid deposition. 
6.3.3 Leucine and rapamycin treatment 
L-leucine (EMD Millipore Corp., Billerica, MA) was dissolved in ultrapure water as 
stock concentration of 0.125 M. It is well established that leucine activates mTORC1. To 
determine optimal mTORC1 activation by leucine, dose-response and time course experiments 
were conducted. The efficacy of leucine was determined by measuring phosphorylation levels of 
proteins downstream of mTORC1, 4E binding protein 1 (4EBP1), and p70S6K1. All cells were 
grown in leucine-free media for either 6, 12, or 24 h. Cells were treated with two doses of 
leucine to give a final concentration of 0.5 mM (postprandial physiological plasma 
concentration) and 1.5 mM (supraphysiological plasma concentration) leucine. All starvation 




(e.g., phosphorylation of 4EBP1 and p70S6K), which were recovered by both doses of leucine 
(Supplemental Fig. S2). Additionally, the role of mTORC1 in leucine activation of translation 
initiation was confirmed by using rapamycin, an inhibitor of mTORC1 (Figure 5.8). Thus, both 
leucine doses were chosen for later experiments. In experiments involving rapamycin (EMD 
Chemicals, San Diego, CA), 100 nM of rapamycin was added to media 1 h before treatments 
with PA and/or leucine. 
6.3.4 RNA isolation and real-time PCR  
RNA samples were isolated using TRIzol (Invitrogen, Waltham, MA), following 
manufacturer instructions. cDNA was synthesized in accordance with manufacturer instructions 
(Roche Lightcycler 480 system). SYBR green master mix (Quanta, Gaithersburg, MD) was used 
as the reporter dye for acetyl- CoA carboxylase (ACC), Cpt1a, peroxisome proliferator-activated 
receptor γ (PPARγ), fatty acid transport protein 1 (FATP1), fatty acid transport protein 4 
(FATP4), sterol regulatory element-binding protein 1 (SREBP1), adenine nucleotide translocase 
type 1 (ANT1), PPAR, mitochondrial transcription factor A (Tfam), uncoupling protein 2 
(UCP2), uncoupling protein 3 (UCP3), nuclear respiratory factor 1 (NRF1) and sirtuin 1 
(SIRT1). All primer sequences are provided in the supplementary material (Table 5.1). 
Glyceraldehyde- 3-phosphate dehydrogenase (GAPDH) was used as an internal reference gene 
to normalize data since it remains constant regardless of treatment. All primers were ordered 
from Integrated DNA Technologies (Coralville, IA). All samples and controls were analyzed in 
duplicate. Relative expression of target genes were determined using 2ΔΔCt method (28). 
6.3.5 Oil red O staining and imaging 
Oil red O staining was performed following the manufacturer’s instructions (American 




PBS. PBS was removed from each well and propylene glycol was added and incubated for 2 
min. Then, propylene glycol was removed, cells were incubated with oil red O stain, which was 
preheated in 60°C water bath, for 6 min. Oil red O stain was removed, and cells were incubated 
with 85% propylene glycol for 1 min. After rinsing with ultrapure water three times, modified 
Mayer’s hematoxylin was used for 1 min. Cells were rinsed again with ultrapure water three 
times. Finally, cells were dried at room temperature, and 10% formalin was added to fix cells. 
Aqueous mounting solution was added and coverslips were placed in each well. Images were 
obtained using an inverted microscope (VWR, Radnor, PA) at 40 × magnification. All cells were 
90% differentiated before treatment was administered. However, it has been shown that 
rapamycin may impact C2C12 hypertrophy (14), which could impact images. Images were 
processed using ImageJ software (National Institutes of Health, Bethesda, MD). The percentage 
of red stain in each image was exported from ImageJ (National Institutes of Health) and analyzed 
using GraphPad Prism Version 6.0 (La Jolla, CA). 
6.3.6 Cell lysate sample collection and Western blotting 
Myotubes were cultured in 35-mm-diameter 6-well plates. After treatment, cell culture 
media was removed and cells were washed once with PBS (VWR, Atlanta, GA). Then 1 × 
Laemmli sample buffer containing 65.8 mM Tris-HCl (pH 6.8), 26.3% (wt/vol) glycerol, 2.1% 
SDS, and 0.01% bromophenol blue with 1% (vol/vol) protein inhibitor cocktail (VWR, Center 
Valley, PA) was added before sample collection. Cell lysate samples were collected and 
incubated at 100°C for physical denaturation. Cell lysate samples were then vortexed and 
centrifuged at 4°C, 12,000 revolutions/min. All primary and secondary antibodies were 
purchased from Cell Signaling Technologies (Danvers, MA). Relative protein content of 




phospho-4EBP1 (p-S65; catalog no. 9456S), p70 ribosomal S6 kinase 1 (p70S6K1; catalog no. 
2708S), phosphop70S6K1 (p-T389; catalog no. 9234S), mitochondrial dynamin-like GTPase 
(Opa1; catalog no. 67589S), microtubule-associated proteins 1A/1B light chain 3B (LC3-II; 
catalog no. 3868S), mTORC1 (catalog no. 2983S), phospho-mTOR (p-S2448; catalog no. 
5536S), p62/SQSTM1 (catalog no. 5114S), and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH; catalog no. 5174S) were examined. All primary antibodies were diluted as the ratio 
1:2,500 (vol/vol), and all secondary antibodies were diluted as the ratio 1:5,000 (vol/vol). Blots 
were developed with enhanced chemiluminescence (VWR). Relative protein content was 
analyzed using a ProteinSimple FluorChem M imager (ProteinSimple, San Jose, CA) and band 
gray values were quantified using ImageJ software. Ponceau S staining was used as a loading 
control. GAPDH was used to normalize Opa1, LC3-II, and p62. Phosphorylated 4EBP1, 
mTORC1, and p70S6K1 were normalized to the total protein content of 4EBP1, mTOR, and 
p70S6K1, respectively. Finally, all treatments were expressed as the fold change compared with 
control. 
6.3.7 Mitotracker imaging 
Mitotracker Red CMXRos (Cell Signaling Technology) lyophilized solid was dissolved 
in 941 µL of DMSO to make a 0.1 mM stock solution. A 4’,6-diamidino-2-phenylindole, 
dihydrochloride (DAPI; Cell Signaling Technology) lyophilized solid was dissolved in ultrapure 
water to reach 20 mg/mL stock. Cells were cultured in a specialized 35-mm fluorodish (World 
Precision Instruments, Sarasota, FL) for immunofluorescence. After treatment, mitotracker red 
probes were directly added into cell culture medium to reach a final concentration of 100 nM and 
incubated 30 min at 37°C. After incubation, cells were washed with twice with PBS and 




fixed with 3.7% formalin for imaging. For cell imaging, an inverted Nikon Ti-E Eclipse Total 
Internal Reflection Fluorescence Microscope equipped with × 100 1.49 numerical apertures oil 
immersion Apo Nikon objective, Zyla 4.2 sCMOS Camera (Andor Technology, Belfast, 
Northern Ireland), and AURA II solid state triggered illuminator with a 4-channel light source 
(395 nm, 485 nm, 560 nm, 640 nm) was used. Images (n = 9 per treatment) were analyzed using 
the “Mito-Morphology” macro for ImageJ software specifically designed for mitochondrial 
measurements (10). 
6.3.8 Statistical analysis 
Summary statistics were calculated for all data. One-way ANOVA followed by Tukey’s 
post hoc test was used to calculate differences between treatment groups. Results are reported as 
mean ± SE. All data analysis was performed using Prism Graph-Pad Software Version 6.0 (La 
Jolla, CA). P < 0.05 was considered statistically significant. 
 
6.4 Results 
Leucine is well known for activating the mTORC1 pathway in multiple cell types (16, 
19), leading to activation of the translation initiation factors, which can increase protein 
synthesis. In Figure 6.1, the ability of leucine to activate translation initiation through an 
mTORC1-dependent manner was validated. 
Both 0.5 mM and 1.5 mM leucine increased phosphorylation of 4EBP1 (P < 0.0001) in 
control C2C12 cells, and the 1.5 mM leucine dose increased phosphorylation of 4EBP1 in PA-




and mTORC1 phosphorylation (P < 0.0001) in control cells. Rapamycin inhibited the effect of 
leucine in both control and PA-treated cells. 
In Figure 6.2, oil red O staining demonstrates that leucine reduces intracellular lipid 
droplet deposition in PA-treated C2C12 myotubes, independently of mTORC1. However, in this 
study, leucine acts independently of mTORC1 to inhibit PA deposition. In the absence of PA, 
there was no effect of either leucine or rapamycin.  
Kelley et al. (21) first demonstrated that the skeletal muscle from individuals with obesity 
has impaired mitochondrial respiratory chain enzyme activity and damaged inner mitochondrial 
membrane morphology. In addition, Ritov et al. (38) reported reduced overall electron transport 
chain enzyme activity in the vastus lateralis muscle from both patients with obesity and patients 
with type 2 diabetes, which was accompanied by a decrease in the relative number of 
mitochondria compared with lean counterparts. Therefore, we wanted to determine whether 1) 
the function or biogenesis of mitochondria is affected by PA treatment in C2C12 myotubes; 2) 
leucine treatment can reverse the effects of PA; and 3) the effects of leucine on PA-treated 
myotubes are mediated by mTORC1 pathway. Treatment with leucine increased expression of 
UCP2 (Figure 6.3A), ANT1 (Figure 6.3C), PGC1α (Figure 6.3D), PPARγ (Figure 6.3E), SIRT1 
(Figure 6.3F), NRF1 (Figure 6.3G), and Tfam (Figure 6.3H) in control cells (Figure 6.3). 
However, 0.5 mM leucine did not increase PGC1α or Tfam expression and 1.5 mM leucine did 
not increase gene expression of UCP2 or ANT1 in control cells. There was no effect of leucine 
on UCP3 (Figure 6.3B), with the exception of 0.5 mM leucine in the presence of rapamycin, 
which increased UCP3 expression. Treatment with rapamycin blunted the effect of leucine on 
expression of ANT1, PPARγ, SIRT1, and Tfam in control cells, suggesting leucine mediates 




effect of rapamycin only on PGC1α compared with control cells; however, the rapamycin, in the 
presence of 0.5 mM leucine, altered the leucine response, resulting in an increase (P < 0.05) in 
PGC1α expression. There was no effect of rapamycin only on NRF1 in the presence of leucine.  
Treatment with PA blunted the effect of leucine on UCP2, UCP3, ANT1, PGC1α (1.5 
mM leucine only), and SIRT1 compared with control cells. In the presence of rapamycin, there 
was a decrease in ANT1, PPARγ, SIRT1, NRF1, and Tfam expression in both PA-treated cells 
and cells treated with PA and leucine. Taken together, these data suggest that leucine regulates 
mitochondrial biogenesis gene expression through mTORC1-independent and mTORC1-
dependent pathways.  
Although changes in mitochondrial biogenesis gene expression were observed, 
mitotracker staining (Figure 6.4A) revealed that the effect on mitochondrial content (Figure 
6.4B), circularity (Figure 6.4C), and area (Figure 6.4D) was not as prevalent. In PA-treated cells, 
treatment with 1.5 mM leucine increased mitochondrial content, average circularity, and area. 
This effect was blunted by rapamycin; however, rapamycin treatment alone had no effect on PA-
treated cells. Opa1 is reported to be a biomarker for indicating mitochondrial fusion (22). Our 
data show that Opa1 was increased in the presence of rapamycin in control cells, which was 
further increased by treatment with 1.5 mM leucine (P < 0.001; Figure 6.5B). Opa1 was 
increased with PA treatment compared with control (via t test between controls; P < 0.0001), and 
leucine increased Opa1 in PA-treated cells (P < 0.01; Figure 6.5D). Rapamycin downregulated 
Opa1 and blunted the effect of leucine in PA-treated cells (P < 0.001). 
Next, we examined the involvement of autophagy in leucine- mediated increase in 
mitochondrial biogenesis and fusion. An important indicator of autophagosome machinery 




control or PA treatment conditions with or without rapamycin. However, treatment with 
rapamycin only increased LC3-II in control cells (P < 0.0001). Treatment with rapamycin and 
1.5 mM leucine increased LC3-II in both control and PA treatment conditions (P < 0.05) 
compared with treatment with 1.5 mM leucine in control and PA-treated conditions in the 
absence of rapamycin. 
Under control conditions (with and without rapamycin), 1.5 mM leucine increased p62 (P 
< 0.05). Rapamycin-only treatment also increased p62 compared with control cells (P < 0.05). 
There was no effect of PA treatment on p62 compared with control cells; however, p62 was 
decreased with PA and rapamycin compared with rapamycin only. Both 0.5 and 1.5 mM 
increased p62 in PA-treated cells compared with PA and PA with rapamycin (P < 0.01). 
Rapamycin reduced the effect of 0.5 and 1.5 mM leucine on p62 in PA-treated cells (P < 0.05). 
As part of the natural cell survival process, damaged organelles are recycled into the 
autophagosome-lysosome system (33). Increased mitophagy (autophagy of mitochondria) would 
explain observed decreased functional mitochondria in palmitate- treated myotubes (Figure 6.4, 
A and B), suggesting mitochondrial fusion may be involved in eliminating impaired 
mitochondria by fusing them together and producing healthy mitochondria (reviewed in Ref. 31). 
Together with mitotracker data, these data suggest that palmitate decreases the number of healthy 
mitochondria and mitochondrial fusion possibly through activation of mitophagy pathways. 
These data also suggest that leucine promotes mitochondrial fusion to protect mitochondria from 
palmitate-induced mitophagy through mTORC1 pathway. 
Since treatment with leucine is able to decrease intracellular fatty acid deposition, a 
process that is inhibited by rapamycin, we assumed that fatty acid metabolism was involved in 




upstream regulator of fatty acid metabolism. We measured gene expression related to fatty acid 
oxidation (Cpt1b), fatty acid synthesis (ACC, SREBP1), fatty acid transport (FATP1 and 
FATP4), and fatty acid gene transcription factor (PPARα). 
Treatment with PA decreased gene expression in ACC, PPARα, FATP1, FATP4, and 
SREBP1 compared with control cells (Figure 6.6). PA increased Cpt1b (Figure 6.6A) expression 
compared with control cells. Both 0.5 and 1.5 mM leucine significantly increased gene 
expression of Cpt1b, ACC (Figure 6.6B), FATP1 (Figure 6.6D), FATP4 (Figure 6.6E), and 
SREBP1 in both control and PA-treated cells. Only 1.5 mM leucine increased PPARα (Figure 
6.6C) in control cells, and both 0.5 mM and 1.5 mM leucine increased PPARα in PA-treated 
cells. In control cells, rapamycin-only increased expression of Cpt1b and decreased expression of 
ACC PPARα, FATP4, and SREBP1 (Figure 6.6F) and the presence of rapamycin blunted the 
effect of leucine on Cpt1b, PPARα, FATP1, FATP4 (1.5 mM leucine, only), and SREBP1 (1.5 
mM leucine, only) under control conditions. Expression of ACC, FATP4, and SREBP1 in 
control cells increased with rapamycin and 0.5 mM leucine. In the presence of PA only, Cpt1b 
was increased compared with control cells. However, expression of ACC, PPARα, FATP1, 
FATP4, and SREBP1 was decreased in PA only compared with control cells. In PA and 
rapamycin-treated cells, there was an increase in Cpt1b, ACC, PPARα, FATP4, and SREBP1 
compared with PA alone. There was no effect of leucine on Cpt1b with PA and rapamycin 
treatment, and ACC expression was decreased in cells treated with leucine, PA, and rapamycin. 
Although treatment with 0.5 and 1.5 mM leucine increased expression of PPAR, FATP1, and 
SREBP1 compared with PA and rapamycin, the effect of leucine was lower when compared with 




These data suggest that fatty acid metabolism could be dysregulated under palmitate 
treatment, leading to increased intracellular fatty acid accumulation, and that leucine could 
promote fatty acid metabolism by upregulating fatty acid synthesis, fatty acid oxidation, and 
fatty acid transport to eliminate accumulated fatty acids through mTORC1. However, these data 
also demonstrate that leucine acts in an mTORC1- independent manner to regulate lipid 
deposition into muscle cells. 
6.5 Discussion 
To our knowledge, the present study is the first to demonstrate that the branched-chain 
amino acid leucine regulates IMCL deposition independently of mTORC1. Instead, inhibition of 
IMCL deposition occurs through regulation of mitochondrial biogenesis and fatty acid oxidation. 
These findings are supported by previous work in our laboratory (3, 12) in which we 
demonstrated that 42 days of leucine supplementation increased PPARγ expression in the 
skeletal muscle of male Sprague-Dawley rats (3). We also demonstrated that diets high in protein 
and leucine decrease IMCL, potentially through downregulation of mTORC1 in male Zucker rats 
(12). 
High-fat feeding has been established as a model to induce obesity in animal models. 
However, there is no well-established model for simulating obesity in cultured muscle cells. One 
of the key differentiating factors in skeletal muscle between animal and human models of normal 
weight and those that are obese is the higher level of IMCL observed (1, 6). Moreover, levels of 
saturated fatty acids, especially the C16:0 fatty acid, palmitate, are higher in the plasma and 
skeletal muscle of individuals with obesity (40). In recent years, treating C2C12 myotubes with 
palmitate has been shown to partially mimic in vivo obese skeletal muscle conditions, such as 




demonstrating that palmitate- treated C2C12 myotubes had almost sevenfold higher IMCL 
content compared with controls, which is similar to observations made in muscle from animal 
models of obesity (1), further establishing this as a viable in vitro model for studying the effects 
of obesity on skeletal muscle. 
Since mitochondria are the primary site for fatty acid beta-oxidation, it has been 
suggested that mitochondrial dysfunction could lead to elevated IMCL deposition in skeletal 
muscle. In the in vivo model reported by Koves and colleagues (23), disordered mitochondrial 
function, including excessive beta-oxidation, is often observed in high fat-fed animals. In support 
of these results, we observed upregulated expression of genes targeting fatty acid oxidation in 
PA-treated cells, accompanied by decreased mitochondrial content in PA-treated cells. This 
aligns with data from studies using obese skeletal muscle, in which elevated expression of genes 
regulating fatty acid oxidation was observed compared with normal-weight counterparts (50). 
The mechanisms related to observed dysfunctional mitochondria in obese skeletal muscle 
are complicated. One explanation for the dysfunction could be through increased autophagy 
signals in mitochondria, also known as mitophagy, which occurs in skeletal muscle. As the 
primary system for recycling damaged subcellular organelles, mitophagy enables myotubes to 
recycle any potential energy from impaired mitochondria. However, under obese conditions, 
dysregulated mitophagy could cause harm to the intramyocellular mitochondrial pool. However, 
markers of autophagy, LC3-II and p62, do not change in the skeletal muscle from individuals 
with obesity (25), which is similar to what we observed in this study (e.g., no change in the LC3-
II protein content in the presence of PA). 
It is well established that leucine initiates protein synthesis through activation of the 




well known is the role of leucine in muscle mitochondria metabolism, especially under obese 
conditions. Sato et al. (41) recently administered leucine to both young rats and C2C12 
myotubes. Administration of leucine upregulated genes related to mitochondrial biogenesis, 
Tfam and PGC1α, in the skeletal muscle of rats and in the C2C12 myotubes. Similar changes 
were observed in this study. This study also demonstrates the ability of leucine to increase 
expression of genes related to mitochondrial biogenesis, such as PGC1α and SIRT1, in C2C12 
myotubes under control conditions and in cells treated with PA. Interestingly, gene expression 
under control conditions is not altered in the presence of rapamycin. However, when cells are 
treated with PA, rapamycin downregulates the effect of leucine on genes related to mitochondrial 
biogenesis, suggesting mTORC1 plays a role. These findings were translated into an increase in 
mitochondrial density in the C2C12 myotubes treated with PA and leucine, an effect that was 
also blunted with rapamycin. This is supported by work by Vaughan et al. (48), who found that 
leucine treatment of C2C12 cells increases mitochondrial density. These data indicate that the 
effect of leucine on mitochondrial biogenesis may to be regulated through mTORC1 under obese 
conditions. 
Despite the increase in mitochondrial density and expression of genes related to 
mitochondrial biogenesis under obese conditions and the potential regulation by mTORC1, 
mTORC1 did play a role in the prevention of lipid deposition in skeletal muscle cells in the 
presence of leucine. Treatment with leucine significantly reduced lipid deposition in C2C12 
myotubes. This could be partially explained by an increase in mitochondrial biogenesis; 
however, Estrada-Alcade et al. (11) demonstrate that in C2C12 myotubes, leucine increased lipid 




Eight months of leucine supplementation in an in vivo model of obesity increased energy 
expenditure and were accompanied by significant elevations in gene expression related to 
mitochondrial oxidative function for genes, such as UCP3, PPARα, and NRF1 (16). However, 
some data suggest that dietary leucine supplementation does not change energy homeostasis, 
protein content of UCPs in adipose and muscle, or body composition (35). Notably, in these 
studies, leucine was only supplemented in a low-fat (5% wt/wt) diet, which means high-fat diet-
induced obesity was not achieved. In another short-term (1-wk) study conducted by the same 
group using a high-fat diet-induced animal model of obesity, the leucine-supplemented group 
demonstrated decreased body weight gain, which could be explained by lower fat mass gain, 
food intake, and energy intake (13). At the transcriptional level, fatty acid synthesis-related 
genes, such as ACC, were downregulated in the liver of the leucine-supplemented group (13). 
The current study has contradictory findings, since we observed upregulation of all genes 
related to fat metabolism in the presence of leucine. Another study showed increased body 
weight, partially because of higher adipose tissue gain, in a chronic leucine-supplemented (24 
wk) diet-induced obese animal model, whereas insulin sensitivity was improved (27). Moreover, 
leucine supplementation in the diet of offspring from rats fed a high-fat diet, showed higher Cpt1 
and PGC1α expression in the skeletal muscle, suggesting leucine improves fatty acid oxidation 
in muscle, which is similar to what we found in the present study. In another in vivo animal 
study, leucine supplementation after diet-induced obesity did not change gene expression related 
to fatty acid metabolism and mitochondrial biogenesis, such as Cpt1 and NRF1 in muscle, but 
did increase expression of genes, such as UCP1, UCP3, and Cpt1 in epididymal white adipose 
tissue and Cox-III, PPARα, UCP3, and Cpt1 in brown adipose tissue. Long-term leucine 




Previous in vivo research from our laboratory also showed increased expression of markers such 
as FAS and PPARγ in skeletal muscle from obese Zucker rats fed with a high-protein diet 
containing a high amount of leucine (12). Moreover, treatment of C2C12 myotubes with 
palmitate and leucine reduced the effect of leucine on regulation of Tfam and PGC1α (19). Here, 
we report upregulation of mitochondrial biogenesis-related gene expression (e.g., PGC1α, 
PPARγ, NRF1, and Tfam) and mitochondrial content observed in palmitate-treated myotubes 
with leucine supplementation. However, the effect of leucine on obesity and skeletal muscle lipid 
deposition is inconsistent in the literature and the results are influenced by both the model of 
obesity (diet-induced obesity vs. genetically modified obese models) and the method of leucine 
administration (in vivo vs. in vitro). 
There are several limitations to this study. First, this is an in vitro model of obesity in 
skeletal muscle using a murine cell line. Although we observed similar morphological changes to 
the in vitro muscle cells as has been observed in muscle from patients with obesity, we are 
working in an isolated cell system without the checks and balances that occur in the presence of 
whole-body systems. Another limitation is that our control cells were void of leucine, which is 
not physiological. Finally, tracer experiments to determine protein synthesis or lipid oxidation 
rates and bioenergetic studies were not performed in this study, which would have allowed us to 
identify physiological outcomes to the mechanistic changes we observed. 
In conclusion, the present study is the first to demonstrate the role of leucine in 
intracellular fatty acid content and the related mechanisms of action in C2C12 muscle cells 
independently of mTORC1. The decrease in IMCL could be explained by an increased number 




also suggests the possible involvement of fatty acid metabolism-related enzymes in leucine-
mediated IMCL reduction. Additional studies are needed to confirm mechanisms of action. 
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8 Figure 6.1. Leucine decreases the intracellular lipid deposition in palmitate (PA)-treated 
C2C12 myotubes. C2C12 myotubes were treated with or without PA. Both groups received 
six treatments: control, rapamycin (RAP), 0.5 mM leucine (0.5 mM Leu), 1.5 mM leucine 
(1.5 mM Leu), 0.5 mM leucine + rapamycin (0.5 mM Leu + RAP), and 1.5 mM leucine + 
rapamycin (1.5 mM Leu + RAP). A: oil red O staining of all treatments. B: quantification of 
oil red O staining. Values not sharing the same letter are significantly different; P < 0.05. 






Figure 6.2. Leucine (Leu) activates translation initiation via the mammalian target of rapamycin 
(RAP) complex (mTORC) 1 pathway in C2C12 myotubes treated with or without palmitate 
(PA). Representative Western blot analysis (A) was performed to determine the phosphorylation 
of mTORC1 on S2448, total mTORC1, phosphorylation (p) of 4E binding protein 1 (4EBP1) on 
S65, total 4EBP1, phosphorylation of p70S6K1 on T389, total p70S6K1, and GAPDH. The 
PVDF membrane was stained by Ponceau S stain to ensure consistency in loading the gel. The 
relative phosphorylation level of 4EBP1 (B), p70S6K1 (C), and mTORC1 (D) were expressed as 
the fold-change to control group and ratio of phosphorylated protein to total protein. Values not 






Figure 6.3. The effect of leucine (Leu) on expression of genes related to mitochondrial 
biogenesis in palmitate (PA)-treated C2C12 myotubes. Gene expression related to mitochondrial 
electron transport chain uncoupling: uncoupling protein (UCP) 2 (A), UCP3 (B), and adenine 
nucleotide translocase type 1 (ANT1) (C). Gene expression related to mitochondrial biogenesis: 
peroxisome proliferator-activated receptor-γ-coactivator-1α (PGC1α) (D), peroxisome 
proliferator-activated receptor γ (PPARγ) (E), sirtuin 1 (SIRT1) (F), nuclear respiratory factor 
(NRF) 1 (G), and mitochondrial transcription factor A (Tfam) (H). Values not sharing the same 






Figure 6.4. The impact of leucine (Leu) on mitochondrial content, circularity, and area in 
palmitate (PA)-treated C2C12 myotubes. A: mitotracker, DAPI, and merged staining of all 
treatment groups. Images were taken under ×100 magnification. B: quantification of percentage 
of cytosol occupied by mitotracker stains. C: average circularity of mitochondria. D: 
area/perimeter ratio of mitochondria. Values not sharing the same letter are significantly 







Figure 6.5. The effect of leucine (Leu) on proteins related to mitochondrial fusion and 
autophagy in palmitate (PA)-treated C2C12 myotubes. A: representative Western blot of 
mitochondrial dynamin-like GTPase (Opa1), microtubule-associated proteins 1A/1B light chain 
3B (LC3-II), p62, and GAPDH. The PVDF membrane was stained by Ponceau S stain to 
determine the loading control. The relative protein content was expressed as the fold change to 
control group. B: Opa1 C: LC3-II. D: p62. Values not sharing the same letter are significantly 







Figure 6.6. Leucine (Leu) promotes gene expression related to fatty acid metabolism in 
palmitate (PA)-treated C2C12 myotubes. Carnitine palmitoyltransferase (Cpt) 1b (A), acetyl-
CoA carboxylase (ACC) (B), peroxisome proliferator-activated receptor α (PPARα) (C), fatty 
acid transport protein (FATP) 1 (D), FATP4 (E), and sterol regulatory element-binding protein 1 
(SREBP1) (F). Values not sharing the same letter are significantly different; P < 0.05. Values 







Figure 6.7. Determination of palmitate treatment time. C2C12 myotubes were differentiated 
from myoblasts under DMEM medium that contained 2% horse serum. Then cells were treated 
with 0.75mM palmitate for four periods of time: 0 hour, 6 hours, 12 hours, and 24 hours. (A) Oil 
red o staining of all treatments. (B) Quantification of oil red o staining of intracellular fatty acid 
indicates 24-hour palmitate treatment led to highest intracellular fatty acid accumulation. 







Figure 6.8. Both 0.5mM and 1.5mM leucine activate mTORC1 pathway, while inhibited by 
rapamycin in C2C12 myotubes. C2C12 myotubes were differentiated from myoblasts under 
DMEM medium that contained 2% horse serum. Then cells were treated by treatments: control, 
rapamycin, 0.5mM leucine, 1.5mM leucine, 0.5mM leucine + rapamycin, and 1.5mM leucine + 
rapamycin. Three treatment times were used for all treatment groups: 6 hours, 12 hours, and 24 
hours. Western blot analysis was performed as described in the Materials and Methods to 
determine the phosphorylation of S65 residue of 4EBP1, total 4EBP1, phosphorylation of T389 







Table 6.1. Sequences of primers used for real-time PCR 
 



















































9 Overall conclusion 
This dissertation includes studies that 1) firstly comparing gene expression related to protein 
breakdown and energy metabolism between young and old, lean and overweight/obese human 
skeletal muscle; 2) firstly linking the gene expression related protein breakdown and energy 
metabolism with whole body protein kinetics; 3) firstly showing leucine can decrease 
intramyocellular lipid deposition in an in vivo model of obesity independent of mTORC1 
pathway. However, further in vivo study is needed to verify the effect of leucine on lipid 
deposition in skeletal muscle in obesity condition. In addition, the effect of leucine on skeletal 
muscle in aging condition is also required. 
